

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
10 February 2005 (10.02.2005)

PCT

(10) International Publication Number  
**WO 2005/012490 A2**

(51) International Patent Classification<sup>7</sup>: **C12N**  
(21) International Application Number:  
PCT/US2004/024571  
(22) International Filing Date: 30 July 2004 (30.07.2004)  
(25) Filing Language: English  
(26) Publication Language: English

(30) Priority Data:  
60/491,565 1 August 2003 (01.08.2003) US

(71) Applicant (for all designated States except US): **ELAN PHARMACEUTICALS, INC.** [US/US]; 800 Gateway Boulevard, South San Francisco, Ca 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ZHAO, Byron** [—/US]; 1036 Colorado Avenue #2R, Palo Alto, CA 94025 (US). **YU, Mei** [—/US]; 2274 Twenty-First Street, San Francisco, CA 94116 (US).

(74) Agent: **GARRETT, Arthur S.**; Finnegan, Henderson, Farrahaw, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC 20005-3315 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NEUROPROTECTIVE EFFECTS OF ATF6

(57) Abstract: The present invention relates to methods for preventing cell death in a subject and the application of these methods for treating neurodegenerative diseases, such as Parkinson's disease, Alzheimer's disease, etc. In one embodiment of the invention, a method for preventing cell death may comprise effecting overexpression of an active form of ATF6 in the cell.



WO 2005/012490 A2

## **NEUROPROTECTIVE EFFECTS OF ATF6**

### **CROSS REFERENCE TO RELATED APPLICATIONS**

- [001] This application claims the benefit of U.S. Provisional Application No. 60/491,565, filed August 1, 2003, which is herein incorporated by reference in its entirety.

### **FIELD OF THE INVENTION**

- [002] The present invention is related generally to methods for preventing cell death by the administration of a functional form of ATF6.

### **BACKGROUND OF THE INVENTION**

#### **Parkinson's disease**

- [003] Parkinson's disease (PD) is one of the most common neurodegenerative diseases, with a prevalence of about 1% in people 65 years of age but increasing to 4%–5% by age 85. The major clinical symptoms of Parkinson's disease include bradykinesia, resting tremor, rigidity, and postural instability. The underlying pathology of the disease is a profound reduction in striatal dopamine content caused by the death of dopaminergic neurons in the substantia nigra (SN) pars compacta. Forno, J. Neuropathol. Exp. Neurol. 55:259-272 (1996). Disease symptoms appear after degeneration of more than 70-80% of the dopaminergic neurons in the substantia nigra.
- [004] Broadly speaking, the disease falls into two categories: late onset and early onset PD. Late onset PD is observed predominantly in patients over the age of 55 and is believed to be mostly the product of environmental factors. Late onset PD leads to dopaminergic neuron death at a faster rate, and to a more

severe degree, than in healthy individuals. Early onset Parkinson's disease is less frequent, with symptoms developing between the ages of 35 and 60.

- [005] PD's distinct pathological lesions of the SN include eosinophilic filamentous inclusions known as Lewy bodies (LBs) and dystrophic neuritis, termed Lewy neurites (LNs). *Id.* The major components of LBs are  $\alpha$ -synuclein and ubiquitin. Over the last few years, two mutations in  $\alpha$ -synuclein have been found to be associated with familial cases of PD, highlighting the importance of  $\alpha$ -synuclein and LBs in the pathogenesis of PD. Polymeropoulos *et al.*, Science 276:2045-2047 (1997).
- [006] At present, the most common therapies for PD involve attempts to increase the dopamine content in patients via the administration of L-DOPA (as a precursor of dopamine), dopamine agonists, or monoamino oxidase B inhibitors (blocking the degradation of dopamine). These treatments alleviate some of the disease symptoms, but, because dopaminergic neurons continue to die, they do not prevent the progression of the disease. At present, there are no prophylactic therapies available to stop the progression of this degenerative disease.

#### **Parkin gene**

- [007] Lately, Autosomal Recessive Juvenile Parkinsonism (ARJP), a form of familial PD, has been linked to mutations in the human chromosome locus 6q25.2-27 ("PARK 2" gene locus, parkin gene). Matsumine *et al.*, Am. J. Hum. Genet. 60:588-596 (1997). Neuropathological examination of patients with a

mutation in this gene demonstrated that neuronal loss and gliosis were restricted to the SN and locus ceruleus, even though in most cases Lewy pathology is not observed. Mori *et al.*, Neurology 51:890-892 (1998); Hayashi *et al.*, Mov. Disord. 15:884-888 (2000). A recent study, however, reports a patient with a mutation in the parkin gene who also developed Lewy pathology. Farrer *et al.*, Ann. Neurol. 50:293-300 (2001).

[008] The parkin gene contains 12 exons spanning more than 500 kb and encodes a protein of the same name containing 465 amino acids (molecular weight of 51,652 Da). The parkin protein is homologous to ubiquitin at the N-terminus and at a RING finger-like motif at the C-terminus. Large scale genetic epidemiological studies indicate that 40-50% of familial cases of Parkinsonism include mutations in parkin. Lucking *et al.*, N. Engl. J. Med. 342:1560-1567 (2000).

[009] Biochemically, parkin has been found to be involved in the ubiquitin proteasome pathway of protein degradation. Shimura *et al.*, Nat. Genet. 25:302-305 (2000); Zhang *et al.*, Proc. Natl. Acad. Sci. USA 97:13354-13359 (2000).

### **The ubiquitin proteasome pathway**

[010] Ubiquitin is believed to have multiple roles in cellular function, including the mediation of various stress responses, repair of damaged DNA, regulation of differential gene expression, modification of histones and receptors, and even control of the cell cycle. Other functions of ubiquitin include its chaperone-like role in the assembly of ribosomal proteins and in response to heat shock.

- [011] Ubiquitin also plays a critical role in selective protein degradation. In particular, the attachment of ubiquitin monomers to a protein earmarks that protein for degradation (ubiquitination) in what is called the ubiquitin proteasome pathway.
- [012] Polyubiquitin chains are the principal signal for targeting substrates to the 26S proteasome. Studies of structurally defined polyubiquitylated model substrates have shown tetraubiquitin to be the minimum signal for efficient proteasomal targeting of a protein. Thrower *et al.*, EMBO J 19:94-102 (2000). Thus, a protein targeted for degradation will have at least four ubiquitin monomers attached to its surface in order to form a polyubiquitin structure having a specific three-dimensional conformation. It is believed that a hydrophobic region produced by this polyubiquitin conformation is important for the specific recognition of the degradation signal by the 26S proteasome. Beal *et al.*, Biochemistry 37(9):2925 (1998).
- [013] Ubiquitin attachment occurs most often in three enzyme-catalyzed steps, although in a few cases ubiquitination is a two-step process. Ubiquitin is first activated by attachment to the ubiquitin-activating enzyme, E1. After an exchange reaction, ubiquitin is transferred to one of several ubiquitin-conjugating enzymes, E2. In some instances, ubiquitin is transferred directly from E2 to the target protein. In most cases, however, ubiquitin is transferred to a ubiquitin ligase, E3, which catalyzes the final attachment of ubiquitin to the target protein. The specificity of the system is conferred primarily by the E3 ligase, of which four different classes have been identified.
- [014] Recent studies have demonstrated that parkin is an E3 ligase. Imai *et al.*, Cell 105:891-902 (2001). Therefore, when parkin mutations undermine

parkin's ability to mediate the degradation of its substrate proteins, accumulation of these proteins occurs in the cell.

### **ATF6 and the Unfolded Protein Response**

- [015] Protein degradation via the ubiquitin proteasome pathway is important in the regulation of cell activity. For example, rapid degradation of regulatory proteins allows the cell to control processes such as DNA repair, cell division, cellular differentiation, etc. Additionally, the ubiquitin proteasome pathway is involved in the degradation of proteins that have failed to fold or assemble correctly in the endoplasmic reticulum (ER).
- [016] In general, as unfolded proteins accumulate in the ER, a stereotypical response, termed the Unfolded Protein Response (UPR), is mounted as an attempt by the stressed cells to eliminate the unfolded proteins. The UPR is an intracellular signaling pathway that relays signals from the lumen of the ER in the presence of unfolded proteins to activate target genes in the nucleus. If the attempt to eliminate unfolded proteins fails, the accumulation of these proteins activates additional stress pathways that ultimately lead to cell death.
- [017] Induction of the UPR in human cells requires activation of both hIre1 and ATF6. van Laar *et al.*, Current Protein and Peptide Science 2:169-190 (2001). hIre1 is a transmembrane protein kinase whose nuclease domain modifies a mRNA that encodes a transcription factor involved in the activation of UPR-responsive genes. Although the substrate mRNA for hIre1 has not been identified, it has been proposed that the substrate is the mRNA encoding ATF6. *Id.*

- [018] ATF6 is a membrane-bound transcription factor that also activates genes associated with the UPR. Ye, J. *et al.*, Mol. Cell 6:1355-1364 (2000). When unfolded proteins accumulate in the endoplasmic reticulum, ATF6 is cleaved releasing its soluble N-terminal domain into the cytoplasm. *Id.* Cleavage of ATF6 occurs in a regulated intramembrane proteolysis (RIP) process, which is, in general, a two-step process. In the first step, the extracytoplasmic domain is cleaved leaving a cytoplasmic domain plus a transmembrane domain containing 25 amino acids or less. Next, a second protease cleaves within the transmembrane sequence liberating the cytoplasmic domain. In the case of ATF6, the first cleavage is catalyzed by site-1 protease (S1P) and the second by site-2 protease (S2P). *Id.*
- [019] Once the cytoplasmic domain of ATF6 enters the nucleus, it activates the transcription of at least three genes encoding chaperone proteins that act to restore the folding of proteins in the ER lumen. Haze *et al.*, Mol. Biol. Cell 10:3787-3799 (1999). Transcription activation by ATF6 of UPR-induced genes involves binding of ATF6 to a consensus sequence called the ER-stress responsive element (ERSE). The ERSE is found in promoters of genes that are activated upon ER-stress. van Laar *et al.*, Current Protein and Peptide Science 2:169-190 (2001) This 19-bp promoter consists of three domains: a CCAAT region and a CCACG region, separated by a 9-bp GC-rich region. van Laar *et al.*, Current Protein and Peptide Science 2:169-190 (2001); Roy *et al.* Nucleic Acids Res. 27:1437-1443 (1999); Yoshida *et al.* J. Biol. Chem. 273:33741-749 (1998). The consensus sequence of ERSE found by Roy *et al.* is CCAATCGGCGGGCGGCCACG (SEQ ID NO: 3). Roy *et al.* Nucleic Acids Res. 27:1437-1443 (1999).

- [020] Recent reports indicate that ATF6 is capable of binding specifically to oligonucleotides containing the sequence (G)(G)TGACGTGG (SEQ ID NO: 1) or the sequence (G)(G)TGACGTGA (SEQ ID NO: 2), where both sequences are different from that of the ERSE. Wang *et al.*, J. Biol. Chem. 275:27013-27020 (2000). The nucleotides in parenthesis showed more variability among the several oligonucleotides tested. Interestingly, the 3' half of these ATF6 consensus DNA binding sites is the complementary sequence of the low affinity binding site for the basal transcription factor YY1 found in the mammalian ERSE. *Id.* Furthermore, Wang *et al.* also found that the full cytoplasmic domain of ATF6 is not necessarily required for binding of ATF6 to the consensus DNA binding sites mentioned above (SEQ ID NO: 1 and SEQ ID NO: 2). Wang and coworkers found specific binding to sequence SEQ ID NO: 1 and SEQ ID NO: 2 by a 145 amino acid-long fragment of ATF6 containing the basic leucine zipper (bZIP) domain. *Id.*
- [021] It has been reported that overexpression of full length ATF6 did not significantly affect the expression of UPR-regulated genes. However, overexpression of the soluble ATF6 cytoplasmic domain did enhance expression of the molecular chaperone BiP. van Laar *et al.*, Current Protein and Peptide Science 2:169-190 (2001). Now, we have found that overexpression of ATF6 prevents death in cells with a defect in their UPR or in their ubiquitin proteasome pathway, which defect produces an undesired accumulation of proteins in that cell.
- [022] One possible mechanism by which an undesired accumulation of proteins occurs in diseases like PD is, for example, through the presence of parkin mutations that trigger accumulation of parkin substrate proteins in the cell.

This accumulation of proteins in turn activates the cell's stress system that culminates in death when the cell is unable to cope with the buildup of proteins.

[023] Even for idiopathic PD patients, who display LBs and show no parkin mutations, sequestration of parkin into LBs could still be a mechanism that deprives the cell of functional parkin. The resulting protein accumulation may be responsible for the loss of nigral dopaminergic neurons in these patients. Shimura *et al.*, Science, 293:263-269 (2001).

[024] It is important to note that the present invention may also be useful in the treatment of other diseases besides PD. A number of other neurodegenerative diseases, such as Alzheimer's disease, are associated with abnormal precipitation and/or aggregation of proteins. Because these varied diseases display many pathological mechanisms in common, it is likely that they share pathways that lead to aberrant aggregation and/or precipitation of proteins and which may be alleviated by the methods presented here for treatment of Parkinson's disease.

#### **SUMMARY OF THE INVENTION**

[025] The present invention relates to methods for preventing cell death. In general, the methods of the invention may be practiced *in vivo* or *in vitro*. When practiced *in vivo*, the methods of the invention provide effective treatment for the condition suffered by a subject. When practiced *in vitro*, the methods of the invention provide a better understanding of the particular disease in question (Parkinson's disease, Alzheimer's disease, etc.), which will allow improved diagnosis and treatment of these diseases.

- [026] In one embodiment of the invention, a method for preventing cell death comprises increasing the amount of a functional form of ATF6 in the cell.
- [027] In another embodiment of the invention, a method for preventing cell death comprises effecting overexpression of a functional form of ATF6 in the cell.
- [028] In another embodiment of the invention, the method for effecting overexpression of a functional form of ATF6 preventing cell death comprises introducing a vector comprising a nucleic acid sequence encoding ATF6 into a cell by methods known in the art. This nucleic acid sequence may be operably linked to one or more transcriptional regulatory sequences, such as promoters, enhancers, activators, terminators, polyadenylation signals, and other regulatory sequences known to the skilled artisan.
- [029] In another embodiment of the invention, the nucleic acid sequence encoding a functional form of ATF6 encodes the full-length form of ATF6. In another embodiment of the invention, the nucleic acid sequence encoding a functional form of ATF6 encodes only the N-terminal domain of ATF6.
- [030] In another embodiment of the invention, the nucleic acid sequence encoding a functional form of ATF6 encodes a functional derivative of either the full-length form of ATF6 or the N-terminal domain of ATF6. Such derivatives may be produced by techniques known in the art, including, but not limited to, deletions, additions, conservative amino acid substitutions, or other manipulations that produce a molecule that retains at least one desired biological function of ATF6 (e.g., prevention of cell death). Amino acid substitutions made in order to prepare derivatives of ATF6 are accomplished by selecting substitutions that do not differ significantly in their effect on maintaining, for example, (a) the structure of the ATF6 peptide backbone in

the area of the substitution, (b) the charge or hydrophobicity of ATF6 at the target site, or (c) the bulk of a side chain. Additionally, one or more amino acids can be deleted or added from either the N-terminus or C-terminus of ATF6 (or both termini) without substantial loss of biological function.

- [031] Wang *et al.* reported specific binding of a fragment of ATF6 containing the bZIP domain to an ATF6-specific DNA sequence. Wang *et al.*, J. Biol. Chem. 275:27013-27020 (2000). Because binding to this sequence by ATF6 is believed to activate transcription of UPR-inducible genes, one embodiment of a nucleic acid sequence encoding a functional form of ATF6 is a nucleic acid sequence encoding the bZIP domain of ATF6 or a functional derivative of the bZIP domain of ATF6.
- [032] In another embodiment of the invention, a method for preventing cell death comprises introducing into a cell a vector comprising a nucleic acid sequence encoding a basal transcription factor that binds to the ER-stress responsive element (ERSE), wherein this vector optionally comprises a nucleic acid sequence encoding a functional form of ATF6. Because the ERSE is part of the promoter region of UPR-inducible genes, the presence of basal transcription factors may enhance the transcription of these genes by ATF6, which is also an ERSE-binding transcription factor.
- [033] In another embodiment of the invention, the basal transcription factor that binds to the ER-stress responsive element may be NF-Y, YY1, a functional derivative of NF-Y or YY1, or any combination thereof, wherein the vector optionally comprises a nucleic acid sequence encoding a functional form of ATF6.

- [034] In another embodiment of the invention, a method for preventing cell death comprises any method known in the art for inducing the expression of ATF6. Induction of the expression of ATF6 may occur, for instance, by inducing the UPR at any point along the signaling pathway between detection of the presence of unfolded proteins in the ER and the expression of ATF6. For example, the expression of ATF6 may be induced by activating the transmembrane kinase Ire1, which has been shown to catalyze the splicing of ATF6 mRNA resulting in a mRNA fragment that encodes only the soluble domain of ATF6. Activation of Ire1 occurs after cleavage of the kinase-nuclease domain of the enzyme by presenilin 1 and 2. Therefore, the expression of ATF6 may be induced by introducing into a cell a vector comprising a nucleic acid sequence encoding one or more molecules chosen from: Ire1, presenilin 1, and presenilin 2.
- [035] In another embodiment of the invention, a method for inducing the expression of ATF6 comprises introducing into a cell a vector containing a nucleic acid sequence encoding a transcription factor of ATF6.
- [036] In another embodiment of the invention, a method for preventing cell death comprises introducing into a cell a vector comprising a nucleic acid sequence encoding either site-1 protease (S1P), site-2 protease (S2P), or both; wherein the vector optionally comprises a nucleic acid sequence encoding a functional form of ATF6. These nucleic acid sequences may be operably linked to one or more transcriptional regulatory sequence.
- [037] In another embodiment of the invention, a method for preventing cell death comprises introducing into a cell a vector comprising a nucleic acid sequence comprising a promoter and/or an enhancer that replaces the original promoter

of the gene encoding ATF6 in the cell's genome. Incorporation of the nucleic acid sequence coding for the promoter and/or enhancer into the cell genomic DNA may occur, for example, by homologous recombination.

- [038] In another embodiment of the invention, a vector comprising any of the nucleic acid sequences useful in the methods of the invention is incorporated into the genome of a cell by nonhomologous recombination.
- [039] Another embodiment of the invention relates to compositions suitable for preventing cell death.
- [040] In another embodiment of the invention, the composition comprises a nucleic acid encoding a functional form of ATF6. Compositions optionally comprise appropriate pharmaceutically acceptable additives, lubricants, diluents, buffers, moistening agents, preservative agents, flavorings, adjuvants, carriers, stabilizers, suspending agents, emulsifying agents, propellants, and/or other vehicles.
- [041] In another embodiment of the invention, the composition comprises a nucleic acid coding for a molecule that regulates the concentration of a parkin-interacting agent in the cell, such as, for example, antisense nucleic acids.
- [042] Another embodiment of the invention relates to methods to screen for substances that affect ATF6 activity. In one embodiment, the method can determine whether a substance increases or decreases the activity of at least one functional form of ATF6 in a cell whose production by a cell evokes a responsive change in at least one characteristic. This method can comprise providing two cell lines, one which produces at least one functional form of ATF6 and a second which produces the at least one functional form of ATF6 at a lower level than the first cell line, or does not produce the at least one

functional form of ATF6 at all. Then, the substance can be placed in contact with the first and second cell lines. Finally, one can compare the at least one characteristic of the first cell line with the second cell line.

[043] Additional objects and advantages of the invention will be set forth in part in the detailed description that follows, and in part will be apparent upon considering the application as a whole. Additionally, further objects and advantages of the invention may also be learned by practicing the invention.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

- [044] Figure 1. Amino acid sequence of human ATF6- $\alpha$  (Swiss-Prot accession number P18850); SEQ ID NO: 4.
- [045] Figure 2. Amino acid sequence of human ATF6- $\beta$  (Swiss-Prot accession number Q99941); SEQ ID NO: 5.
- [046] Figure 3. Amino acid sequence of murine ATF6-  $\alpha$ ; SEQ ID NO: 6.
- [047] Figure 4. Amino acid sequence of murine ATF6- $\beta$  (Swiss-Prot accession number O35451); SEQ ID NO: 7.
- [048] Figure 5. DNA sequence of human ATF6- $\alpha$  (GenBank accession number NM\_007348); SEQ ID NO: 8.
- [049] Figure 6. DNA sequence of human ATF6- $\beta$  (GenBank accession number NM\_004381); SEQ ID NO: 9.
- [050] Figure 7. DNA sequence of murine ATF6- $\alpha$  (GenBank accession number AK087000); SEQ ID NO: 10.
- [051] Figure 8. DNA sequence of murine ATF6- $\beta$  (GenBank accession number AK090378); SEQ ID NO: 11.

### DETAILED DESCRIPTION OF THE INVENTION

- [052] The embodiments described and the terminology used herein are for the purpose of describing exemplary embodiments only, and are not intended to be limiting. The scope of the present invention is intended to encompass additional embodiments not specifically described herein, but that would be apparent to one skilled in the art upon reading the present disclosure and practicing the invention.
- [053] Other than in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in this application are to be understood as being modified in all instances by the term "about." Accordingly, unless the contrary is indicated, the numerical parameters set forth in this application are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.
- [054] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
- [055] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art

to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice of the present invention, exemplary methods and materials are described for illustrative purposes. All publications mentioned in this application are incorporated by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.

[056] Additionally, the publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates, which may need to be independently confirmed.

[057] It must be noted that as used herein and in the appended claims, the singular forms "a", "and", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an antibody" includes a plurality of such antibodies and reference to "a vector" includes reference to one or more vectors and equivalents thereof known to those skilled in the art.

[058] Methods, techniques, and/or protocols (collectively "methods") that can be used in the practice of the invention are not limited to the particular examples of these procedures cited throughout the specification but embrace any procedure known in the art for the same purpose. For example, with respect to methods for the delivery of nucleic acids to the brain, the present invention is not limited to the protocols cited herein, but includes any method available in the art to the skilled artisan to deliver nucleic acids to brain cells.

[059] Furthermore, although some methods may be described in a particular context in the specification, their use in the instant invention is not limited to that context. For example, methods to prepare functional derivatives of a molecule will be described in the context of derivatives of ATF6 but these methods are equally applicable to the preparation of derivatives of any other molecule useful in the methods of the invention.

### Definitions

[060] The terms "nucleic acid" or "polynucleotide" refer to a polymer of at least two nucleotides. The term nucleic acid includes deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). RNA includes, but is not limited to, tRNA (transfer RNA), snRNA (small nuclear RNA), rRNA (ribosomal RNA), mRNA (messenger RNA), anti-sense RNA, and ribozymes. Similarly, DNA includes, but is not limited to, plasmid DNA, viral DNA, linear DNA, chromosomal DNA, or derivatives of these groups. In addition, these forms of DNA and RNA may be single, double, triple, or quadruple stranded. The term nucleic acid also includes PNAs (peptide nucleic acids), phosphorothioates, and other variants of the phosphate backbone of native nucleic acids. In some cases, when a nucleic acid encodes a polypeptide to be introduced into a cell, it may be advantageous, although not necessary, that such nucleic acid be in the form of a double-stranded cDNA lacking intron segments.

[061] A nucleic acid may be constructed to express a whole or partial protein. Once a polynucleotide has been delivered to a cell, the nucleic acid can remain separate from the endogenous genetic material. Alternatively, the nucleic acid could recombine with (become a part of) the endogenous genetic material. For example, DNA can be inserted into chromosomal or genomic

DNA by either homologous or nonhomologous recombination. Homologous recombination is described, for example, in U.S. Patent Nos. 5,282,071, and 5,578,461. Nonhomologous recombination is described, for example, in PCT Application No. WO 00/49162.

- [062] Optionally, depending on their particular function, nucleic acid molecules may be operably linked to one or more transcriptional regulatory sequences.
- [063] One embodiment of the term vector refers to a polynucleotide having a nucleotide sequence that can assimilate other nucleic acid sequences, and propagate those sequences in an appropriate host. A vector may be capable of self-replication or may simply serve as carrier for a given nucleic acid sequence. Vectors may originate from viruses, plasmids, or the cells of a higher organism, and often contain DNA sequences from several sources. Examples of vectors include plasmids, cosmids, and yeast artificial chromosomes. Examples of viral vectors include adenovirus vectors, adenoassociated viral vectors (AAV), and retrovirus vectors. Non-viral vectors include expression plasmid vectors typically used in mammalian cells, and are exemplified by pBK-CMV, pCAGGS, pcDNA3.1, pZeoSV, and the like. See, e.g., European Patent Application Nos. 1 122 312 and 1 132 098.
- [064] Another embodiment of the term vector refers to a carrier used to introduce a nucleic acid sequence into a cell. This type of vector may form complexes with the nucleic acid sequence, for example, an antisense oligonucleotide complexed to protein, an antisense oligonucleotide complexed with lipid-based nucleic acid transduction systems, or other non-viral carrier systems. Suitable lipids and related analogs are described in U.S. Patent Nos. 5,208,036, 5,264,618, 5,279,833, and 5,283,185. Vectors can also be

particulate carriers, examples of which include polymethyl methacrylate polymers and polylactides and poly(lactide-co-glycolides). See, e.g., McGee *et al.*, J. Micro Encap. (1996).

- [065] Several non-viral methods for the transfer of polynucleotides into cultured mammalian cells are also contemplated by the present invention, and include, without being limited to, calcium phosphate precipitation; DEAE-dextran; electroporation; direct microinjection; DNA-loaded liposomes; and receptor-mediated transfection. These techniques are disclosed in, e.g., PCT patent application WO 01/42451. Some of these techniques may be successfully adapted for *in vivo* or *ex vivo* use.
- [066] Vectors are normally used to mediate the expression of a molecule of interest in a cell, in which case they are called expression vectors. An “expression vector” is a vector in which the nucleic acid sequence encoding a molecule of interest is operably linked to suitable transcriptional regulatory sequences capable of effecting the expression of the molecule of interest in a cell.
- [067] A nucleic acid is operably linked when it is placed into a functional relationship with another nucleic acid sequence. For example, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence.
- [068] A transcriptional regulatory sequence is a nucleic acid sequence that regulates the expression of a nucleic acid sequence to which it is operably linked. A regulatory sequence may include elements that are naturally responsible for expressing a particular nucleic acid or may include sequences of a different origin. In general, regulatory sequences can be sequences of eukaryotic or viral genes or derived sequences that stimulate or repress

transcription of a gene in a specific or non-specific manner and in an inducible or non-inducible manner. Transcriptional regulatory sequences include, e.g., promoters, origins of replication, RNA splice sites, enhancers, transcriptional termination sequences, signal sequences which direct the polypeptide into the secretory pathways of the target cell. As the skilled artisan will appreciate, regulatory sequences may be constitutive or inducible depending on the particular nature of the sequence and the role of the nucleic acid sequence operably linked to the regulatory sequence.

[069] A promoter is a transcriptional regulatory sequence that directs RNA polymerase to bind to DNA and initiate RNA synthesis. A strong promoter is one that causes mRNAs to be initiated at high frequency. Examples of promoters that can be used in the construction of vectors for the delivery of nucleic acid sequences to neuronal tissue include the promoter/enhancer from the human cytomegalovirus (hCMV) (WO 98/46273), and the simian virus 40 (SV40) promoter (Harada *et al.*, Cancer Gene Ther. 7(5):799-805 (2000)). Other promoters that cause expression in the brain include the platelet-derived growth factor (PDGF) promoter (WO 02/26936); prion promoter (Hsiao *et al.*, Science 274:99-102 (1996); and the neuron-specific enolase promoter (Xu R., *et al.* Gene Ther. 8(17):1323-32 (2001)).

[070] An enhancer is a transcriptional regulatory sequence that increases transcription by a promoter. Enhancers can effectively increase transcription when located either 5' or 3' to the transcription unit. They are also effective if located within an intron or within the coding sequence itself. Typically, viral enhancers may be used, including SV40 enhancers, cytomegalovirus enhancers, polyoma enhancers, and adenovirus enhancers. See, e.g.,

WO 98/55616 and U.S. Patent Nos. 6,248,555 and 6,323,030. Enhancer sequences from mammalian systems are also commonly used, such as the mouse immunoglobulin heavy chain enhancer. *See, e.g.*, WO 92/04440.

[071] A transcriptional terminator sequence refers either to a sequence that provides a signal that terminates transcription by the polymerase that recognizes the selected promoter or to a signal sequence for polyadenylation. These terminator sequences may be isolated from bacteria, fungi, viruses, animals and/or plants. In the case of terminators from prokaryotic cells, the terminator generally includes a polyadenylation signal, which facilitates the addition of polyadenylate sequences to the 3' end of a primary transcript. Examples of terminators include those from the cytomegalovirus and SV40 systems, as well as the bovine growth hormone (BGH) polyadenylation sequence. *See, e.g.*, WO 98/55616, WO 02/16594 and U.S. Patent Nos. 6,248,555 and 6,323,030.

[072] Mammalian expression vector systems may include a selectable marker gene. Examples of suitable markers include the dihydrofolate reductase gene (DHFR), the thymidine kinase gene (TK), fluorescent green protein,  $\beta$ -galactosidase, or prokaryotic genes conferring drug resistance. The first two marker genes are normally used with mutant cell lines that lack the ability to grow without the addition of thymidine to the growth medium. Transformed cells can then be identified by their ability to grow on non-supplemented media. Examples of prokaryotic drug resistance genes useful as markers include genes conferring resistance to G418, mycophenolic acid, and hygromycin. *See, e.g.*, U.S. Patent No. 6,165,793

- [073] In the context of the invention, overexpression of ATF6 occurs when a functional form of ATF6 is expressed in a modified host cell at higher levels than in the original host cell. An original host cell becomes a modified host cell after any manipulation that alters the expression of any molecule in the original host cell. An example of a modification that alters the expression of ATF6 in the original host cell includes the introduction of a nucleic acid sequence encoding, for instance, ATF6 under a strong promoter.
- [074] Inducing the expression of ATF6 may be accomplished by any modification of the host cell that will result in or increase the expression of ATF6. For example, induction may be carried out by introducing a nucleic acid sequence into the host cell, wherein the nucleic acid sequence encodes transcription factors of ATF6, proteases that catalyze the cleavage of the full-length transmembrane form of ATF6, or any other molecule that directly or indirectly may initiate transcription of ATF6.
- [075] Alternatively, induction may also be effected by exposing the host cell to suitable environmental conditions. For example, environmental conditions that may induce expression of ATF6 include incubation of the cell in the presence of tunicamycin or any other inhibitor of protein folding known in the art.
- [076] The expression of an endogenous protein, for example endogenous ATF6, refers to the expression of the original protein gene in a host cell. Expression of an exogenous gene refers to the expression of a nucleic acid sequence that has been introduced into the cell. The invention contemplates, for example, altering the expression of the endogenous ATF6 gene by replacing the endogenous promoter with an exogenous promoter sequence.

[077] A UPR-regulated gene is a gene that codes for a protein that is involved in a cell's response to ER-stress, such as the unfolded protein response.

Alternatively, these genes are also called, *inter alia*, UPR-induced genes or

UPR-responsive genes. The promoter region of a UPR-regulated gene

comprises the ERSE consensus sequence. van Laar *et al.*, Current Protein and Peptide Science 2:169-190 (2001); Roy et al. Nucleic Acids Res.

27:1437-1443 (1999); Yoshida et al. J. Biol. Chem. 273:33741-749 (1998).

An example of a UPR-regulated gene include the molecular chaperones BiP. van Laar *et al.*, Current Protein and Peptide Science 2:169-190 (2001).

However, UPR-regulated genes include a wide variety of genes that are involved in various aspects of ER function that include not only protein folding, but also protein glycosylation, secretion, degradation, and membrane biosynthesis, among others. *Id.* ATF6-regulated genes include, but are not limited to, UPR-regulated genes.

[078] A therapeutically beneficial effect of a modification of an original host cell is obtained when the modified host cell shows a measurable improvement in a desired characteristic (e.g., prevention of cell death) with respect to the original host control. A therapeutically beneficial effect may come about, for example, as a result of overexpression of a given protein in the cell, for instance ATF6.

[079] A functional form of ATF6 is any form of ATF6 whose overexpression, directly or indirectly, produces a beneficial therapeutic effect in the host cell. For the purposes of this invention, a functional form of ATF6 includes, but is not limited to, a full-length form of ATF6, an N-terminal domain of ATF6, a bZIP-

ATF6 fragment of ATF6 and/or a functional derivative of any of these forms of ATF6.

[080] Unless otherwise explicitly specified in this application, any reference to ATF6 should also be construed as a reference to the full-length form of ATF6, the N-terminal domain of ATF6, a bZIP-ATF6 fragment of ATF6, a functional derivative of the full-length form of ATF6, a functional derivative of the N-terminal domain of ATF6, a functional derivative of a bZIP-ATF6 fragment of ATF6, or any combination of any of these forms of ATF6. This construction should be applied unless the context clearly indicates that only a particular form of ATF6 is being referenced.

[081] The full-length form of ATF6 is a single-pass type 2 transmembrane protein that undergoes regulated intramembrane proteolysis (RIP). Examples of the full-length form of ATF6 include the polypeptides coded by human and mouse ATF6. See Figures 1-4. As defined here, the N-terminal domain of ATF6, also termed the active form or mature form of ATF6, includes any of the polypeptides resulting from cleavage of the full-length form of ATF6 by either S1P or S2P. The ATF6 cleavage sites for S1P and S2P are disclosed in Ye et al (2000). Additionally, the N-terminal domain of ATF6 encompasses a bZIP-ATF6 fragment. A bZIP-ATF6 fragment is any polypeptide of ATF6 that comprises the bZIP domain of ATF6 and that is able to effect transcription of the natural target genes for which ATF6 is a transcription factor. Whether a bZIP-ATF6 fragment can effect transcription of the natural target genes for which ATF6 is a transcription factor can be determined by measuring the therapeutic effect, if any, of the overexpression in a cell of the bZIP-ATF6 fragment. If the cell shows a therapeutically beneficial effect with respect to

the original host cell as shown in the methods of the invention, it can be concluded that the bZIP-ATF6 fragment can effect transcription of the natural target genes for which ATF6 is a transcription factor.

[082] A functional derivative of a given protein is any molecule derived or obtained from that protein that retains at least one desired biological function of the original protein. For example, a functional derivative of ATF6 retains at least one desired biological function of ATF6 if the overexpression of the derivative produces a therapeutically beneficial effect in a host cell. Functional derivatives may be produced by techniques known in the art, including deletions or additions of amino acids, conservative amino acid substitutions, or other manipulations that will not affect the ability of the derivative to provide a therapeutically beneficial effect to the modified host cell.

[083] Substitution of an amino acid may involve a conservative or nonconservative amino acid substitution. Conservative amino acid substitution means replacing an amino acid residue with another amino acid having similar chemical or physical properties (e.g., structure, size, charge, acidity or basicity, hydrophobicity, etc.) and that does not affect the ability of the derivative to retain at least one desired biological function of the original protein. Analogously, a non-conservative substitution refers to the substitution of an amino acid residue with another amino acid having dissimilar chemical or physical properties. Computer programs that predict the effect of a specific amino acid substitution or mutation on the structure of the protein are known in the art. For example, PCT Patent Application No. WO 02/543063 discloses one such method and also reviews the state of the art in this field.

- [084] A derivative may also result from the cleavage of the parent molecule, cyclisation and/or coupling with one or more additional moieties that improve solubility, altering the lipophilic characteristics to enhance uptake by cells, altering stability or biological half-life, decreasing cellular toxicity, or, in particular *in vitro* or *ex vivo* applications, acting as a label for subsequent detection, or the like. Moreover, a derivative may result from post-translational or post-synthesis modification such as the attachment of carbohydrate moieties or chemical reaction(s) resulting in structural modification(s) such as the alkylation or acetylation of amino acid residues or other changes involving the formation of chemical bonds.
- [085] Optimal alignment is defined as an alignment giving the highest percent identity score. An alignment may be optimized, for example, using a variety of commercially available sequence analysis programs, such as BLAST (Basic Local Alignment Search Tool) program available from the National Center for Biotechnology information at <http://www.ncbi.nlm.nih.gov>. See also Altschul, S.F. *et al.*, "Basic local alignment search tool." J. Mol. Biol. 215:403-410 (1990). Local alignment, as opposed to global alignment, analyzes similarities between sequences based on fragments of a longer sequence and is able to detect relationships among sequences which share only isolated regions of similarity. Therefore, local alignment is useful when analyzing sequences of different lengths or in the analysis of multiple regions of similarity within long DNA (or protein) sequences. Other local alignment programs include LALIGN using a ktup of 1, default parameters and the default PAM. The LALIGN program is found in the FASTA version 1.7 suite of sequence comparison programs. Pearson, W. R. *et al.*, PNAS 85:2444-2448 (1988); Pearson, W.

R., Methods in Enzymology 183:63-98 (1990). Computer-assisted alignment also can be performed using the CLUSTAL-W program in MacVector, operated with default parameters and a BLOSUM similarity matrix. Global sequence alignment can be performed using, for example, the FASTD13 computer program based on the algorithm of Brutlag *et al.* (Comp. App. Biosci. 6:237-245 (1990)).

- [086] Percent sequence identity with respect to two amino acid or polynucleotide sequences, refers to the percentage of residues that are identical in the two sequences when the sequences are optimally aligned. Thus, 80% amino acid sequence identity means that 80% of the amino acids in two or more optimally aligned polypeptide sequences are identical. If a gap needs to be inserted into a first sequence to optimally align it with a second sequence, the percent identity is calculated using only the residues that are paired with a corresponding amino acid residue (*i.e.*, the calculation does not consider residues in the second sequences that are in the "gap" of the first sequence).
- [087] A first polypeptide or polynucleotide region is said to be homologous to a second polypeptide region when the regions are essentially co-extensive when the sequences containing the regions are aligned using a sequence alignment program, as described above. Homologous sequences are referred to as corresponding to one another.
- [088] Homologous polynucleotide or polypeptide fragments typically contain a similar, if not identical, number of residues. It will be understood, however, that corresponding fragments may contain insertions or deletions of residues with respect to one another, as well as some differences in their sequences.

[089] The term sequence identity means nucleic acid or amino acid sequence identity in two or more aligned sequences, aligned as defined above.

Sequence similarity between two polypeptides is determined by comparing the amino acid sequence and any conservative amino acid substitutions of one polypeptide to the sequence of a second polypeptide. Thus, 80% protein sequence similarity means that 80% of the amino acid residues in two or more aligned protein sequences are conserved amino acid residues, *i.e.* are conservative substitutions.

[090] Hybridization includes any process by which a strand of a nucleic acid joins with a complementary nucleic acid strand through base-pairing. Thus, strictly speaking, the term refers to the ability of the complement of the target sequence to bind to the test sequence, or vice-versa.

[091] While it is understood that the lower the salt concentration, the higher the stringency, in general, hybridization conditions are based on the melting temperature ( $T_m$ ) of the nucleic acid binding complex or probe at a given ionic strength and are typically classified by the degree of stringency of the conditions under which hybridization is measured. For example, maximum stringency typically occurs at about  $T_m - 5^\circ\text{C}$  ( $5^\circ\text{C}$  below the  $T_m$  of the probe) with salt concentrations in the washing solution typically being 0.1x SSC (20x SSC=3.0 M NaCl/0.3 M trisodium citrate). High stringency typically occurs at about  $5-10^\circ\text{C}$  below the  $T_m$ ; intermediate stringency at about  $10-20^\circ\text{C}$  below the  $T_m$  of the probe; and low stringency at about  $20-25^\circ\text{C}$  below the  $T_m$ . See, *e.g.*, U.S. Patent Nos. 6,051,385 and 6,111,090. Functionally, maximum stringency conditions may be used to identify nucleic acid sequences having identity or near-identity with the hybridization probe; while high stringency

conditions may be used to identify nucleic acid sequences having about 80% or more sequence identity with the probe. Persons skilled in the art will appreciate that specific conditions will vary according to the composition of the probe, composition of the target substrate, and the like. An example of high stringency conditions for a probe having a  $T_m$  of 70°C includes hybridization at about 65°C in about 5x SSPE and washing at about 65°C in about 0.1x SSPE (where 1x SSPE = 0.15 M sodium chloride, 0.010 M sodium phosphate, and 0.001 M disodium EDTA). Examples of various conditions of stringency are taught in Wahl and Berger (Methods Enzymol. 152:399-407(1987)) and Kimmel (Methods Enzymol. 152:507-511 (1987)). One general guide for nucleic acid hybridization is Tijssen, "Laboratory Techniques in Biochemistry and Molecular Biology" Elsevier, vol.24, Hybridization with Nucleic Acid Probes, Part I Overview of principles of hybridization and the strategy of nucleic acid assays (1993).

[092] In the context of the invention, a cell in need of a method for preventing cell death is a cell in which undesired accumulation of proteins occurs. For example, such a cell may include a cell in which parkin substrates accumulate due to the inability of endogenous parkin protein to mediate their degradation. Other examples may include cells in which neurofibrillary tangles (NFT) accumulate, for instance in patients with Alzheimer's disease, etc. Similarly, a subject in need of a method for preventing cell death is a subject in which undesired accumulation of proteins causes cell death.

[093] The terms effective dose, effective amount, therapeutically effective amount, and the like mean administering an agent in an amount sufficient to provide the desired physiological, pharmacological, and/or cognitive change. This will

vary depending on the patient, the disease, and the treatment. The amount may either be a dose for the treatment in a subject believed to have a particular disorder, in which case it should sufficiently alleviate or ameliorate the symptoms of the disorder or condition, or be a prophylactic dose, in which case it should be sufficient to prevent, partially or completely, the appearance of symptoms in the subject.

[094] The terms treatment, treating and the like are used herein to mean obtaining a desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disease or a symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disease and/or an adverse effect attributable to the disease.

Treatment as used herein covers any treatment of a disease in a mammal, for example a human, and includes:

[095] (a) preventing the disease from occurring in a subject that may be predisposed to the disease but not yet diagnosed as having it;

[096] (b) altering the progression of the disease, *i.e.*, slowing or arresting its development; or

[097] (c) reducing the severity of the disease, *i.e.*, causing regression of the disease or alleviating one or more symptoms of the disease.

[098] **Abbreviations**

ARJP    Autosomal Recessive Juvenile Parkinsonism

bZIP    Basic leucine zipper

CMV    Cytomegalovirus

|       |                                                     |
|-------|-----------------------------------------------------|
| ER    | Endoplasmic reticulum                               |
| ERSE  | ER-stress responsive element                        |
| hIre1 | A human transmembrane protein kinase                |
| Ire1  | A transmembrane protein kinase                      |
| LB    | Lewy body                                           |
| LN    | Lewy neurite                                        |
| NFT   | Neurofibrillary tangles                             |
| NF-Y  | A basal transcription factor that binds to the ERSE |
| PD    | Parkinson's disease                                 |
| RIP   | Regulated intramembrane proteolysis                 |
| S1P   | Site 1 protease                                     |
| S2P   | Site 2 protease                                     |
| SN    | Substantia nigra                                    |
| SOD1  | Superoxide dismutase 1                              |
| UPR   | Unfolded Protein Response                           |
| YY1   | A basal transcription factor that binds to the ERSE |

### **General Aspects of the Invention**

[0099] The present invention relates to methods for preventing cell death. For example, preventing neuronal cell death is contemplated within the present invention, including preventing the death of nigral neurons in a mammal, including humans.

[0100] In general, the methods of the invention may be practiced *in vivo* or *in vitro*. When practiced *in vivo*, the methods of the invention will provide effective

treatment for the condition suffered by the subject. When practiced *in vitro*, the methods of the invention will provide a better understanding of the particular disease in question (Parkinson's disease, Alzheimer's disease, etc.) that will allow improvement of the diagnosis and treatment of these diseases.

[0101] One aspect of the present invention is based on the unexpected discovery that overexpression of ATF6 in a cell prevents cell death that would otherwise occur when an undesired accumulation of proteins occurs in that cell. For example, the invention may be useful for treating a condition such as Parkinson's disease (PD) associated with the abnormal accumulation of molecules that interact with parkin and that are not properly disposed of within a cell.

[0102] Additionally, the present invention may also be useful in the treatment of other diseases besides PD. A number of other neurodegenerative diseases are associated with abnormal precipitation and/or aggregation of proteins. For example, the brains of patients with Alzheimer's disease exhibit neurofibrillary tangles (NFT), senile plaques, and cerebrovascular deposits of amyloid-beta; the brains of patients with prion disorders exhibit plaques comprising prion proteins; the brains of patients with Huntington's disease exhibit huntingtin precipitates; patients with dominantly inherited spinocerebellar ataxias exhibit corresponding ataxin protein precipitates; patients with multiple system atrophy exhibit alpha-synuclein deposits; patients with progressive supranuclear palsy exhibit tau precipitates; and patients with familial amyotrophic lateral sclerosis exhibit SOD1 precipitates. See, e.g., Johnson, W.G., J. Anat. 4:609-616 (2000). Because these various diseases share common pathological mechanisms, it is likely that they share pathways that

lead to aberrant aggregation and/or precipitation of proteins. Hardy, J. and Gwinn-Hardy, K., Science 282(5391):1075-1079 (1998).

[0103] The present invention is intended to be used as either a stand-alone therapy, or as a conjunctive therapy with other agents that are either palliative (e.g., agents that relieve the symptoms of the disorder to be treated), and/or agents that target the etiology of the disorder. For example, the administration to a subject of a composition that increases the expression of ATF6 may be carried out in conjunction with the administration of L-DOPA, dopamine agonists, monoamine oxidase B inhibitors, or any other composition useful in the treatment of a neurodegenerative disease, such as Parkinson's disease.

[0104] Any method known in the art that increases the expression of ATF6 in a neuron is part of the invention. In one embodiment of the invention, a method for preventing cell death may comprise introducing a vector comprising a nucleic acid sequence encoding a functional form of ATF6 into a cell by gene therapy methods known in the art.

### **Gene Therapy**

[0105] Examples of amino acid and DNA sequences of ATF6 are shown in Figures 1-8. Construction of an expression vector comprising ATF6 operably linked to one or more transcriptional regulatory sequences may be accomplished by techniques known to those skilled in the art and the use of appropriate vectors.

[0106] An appropriately constructed expression vector may contain, for example, an origin of replication for autonomous replication in the host cells, one or more selectable markers, a limited number of useful restriction enzyme sites, a

potential for high copy number, and active promoters. Expression vectors may originate from a variety of sources such as viruses, plasmids, or the cells of a higher organism.

[0107] The vectors of the invention may be introduced either *ex vivo* (where the cells to be transfected are first removed from the subject to be treated) or *in vivo*, and may result in transient or stable expression on the gene product. Methods of introducing the vectors include viral-based approaches and nonviral approaches, such as lipofection, ligand-DNA conjugates and direct injection of naked DNA. *See, e.g.*, U.S. Patent No. 6,140,484.

[0108] In the case of viral-mediated gene transfer, host cells are transfected with vectors of the present invention by infection with mature virions containing hybrid vectors (the nucleic acid sequences of the invention along with selected viral sequences). The virions used to transfect host cells are preferably replication-defective, such that the virus is not able to replicate in the host cells.

[0109] The virions may be produced by co-infection of cultured host cells with a helper virus. Following coinfection, the virions are isolated (e.g., by cesium chloride centrifugation) and any remaining helper virus is inactivated (e.g., by heating). The resulting mature virions contain a vector of the present invention and may be used to infect host cells in the absence of helper virus. Alternatively, high titers of replication-defective recombinant virus, free of helper virus, may be produced in packaging cell lines containing those components for which the virus is defective. Miller, A. D., *Hum. Gene Ther.* 1:5 (1990).

[0110] Several types of viruses, including retroviruses, adeno-associated virus (AAV), herpes virus, vaccinia virus, and several RNA viruses may be amenable for use as vectors in the present invention. Each type of virus has specific advantages and disadvantages, which are appreciated by those of skill in the art. For example, retroviral and AAV vectors are more suitable for stable transfection than are adenovirus, vaccinia virus, or polio virus vectors. Methods for manipulating viral vectors are also known in the art. See, e.g., U.S. Patent No. 6,140,484.

[0111] Retroviruses, like adeno-associated viruses, stably integrate their DNA into the chromosomal DNA of the target cell. Unlike adeno-associated viruses, however, retroviruses typically require replication of the target cells in order for proviral integration to occur. Accordingly, successful gene transfer with retroviral vectors depends on the ability to at least transiently induce proliferation of the target cells.

[0112] Retroviral vectors are attractive in part due to the efficiency of transfection—some vectors can stably transduce close to 100% of target cells. The use of retroviral vectors for *in vivo* gene therapy has been limited, in part, by the requirement of appropriate viral receptors on the target cell. Because the identities of most retroviral receptors are unknown, it has not been possible to determine the distribution of receptors in different cell types. Accordingly, the targeting of specific cell types by retroviral vectors has in many cases proven problematic.

[0113] However, this difficulty may be circumvented by modifying the envelope protein of the retrovirus to contain a ligand for a known endogenous (not necessarily viral) receptor expressed on the target cells. An application of this

technique is described in detail by Kasahara, N. *et al.*, Science 266:1373 (1994). The virus may also contain an unmodified envelope protein to facilitate cell entry. Adeno-associated viruses are capable of efficiently infecting nondividing cells and expressing large amounts of gene product. Furthermore, the virus particle is relatively stable and amenable to purification and concentration. Replication-defective adenoviruses lacking portions of the E1 region of the viral genome may be propagated by growth in cells engineered to express the E1 genes. Most of the currently-used adenovirus vectors carry deletions in the E1A-E1B and E3 regions of the viral genome. A number of preclinical studies using adenoviral vectors have demonstrated that the vectors are efficient at transforming significant fractions of cells *in vivo*, and that vector-mediated gene expression can persist for significant periods of time (Rosenfeld, M. A., *et al.*, Cell, 68:143-155 (1992); Quantin, B., *et al.*, Proc. Natl. Acad. Sci. U.S.A. 89:2581 (1992); Stratford-Perricaudet, L. D., *et al.*, J. Clin. Invest. 90:626 (1992); Stratford-Perricaudet, L. D., *et al.*, Bone Marrow Transplant 9(suppl. 1):151 (1992); Jaffe, H. A., *et al.*, Nat. Genet. 1:374 (1992).

[0114] Herpes virus vectors are well suited for the delivery and expression of foreign DNA in cells of the central nervous system (CNS), since they can efficiently infect mature, postmitotic neurons. Methods for manipulating the vectors and transfecting CNS cells are well known in the art. See, *e.g.*, U.S. Patent No. 6,140,484 for various references. Studies utilizing direct injection of vectors into CNS tissue have also been performed (*e.g.*, Zhang, *et al.*, Neuroreport, 3:700 (1992).

[0115] In general, the expression vector may be introduced into a host cell via any one of a number of techniques including, but not limited to, transformation, transfection, infection, protoplast fusion, and electroporation. These methods may be used as required in *in-vitro* or *in-vivo* procedures.

[0116] Plasmids or vectors of the present invention may also be purified and injected directly into a target tissue, using naked DNA injection. Further, liposomes may be employed to deliver genes to target tissues using methods known in the art. See, e.g., U.S. Patent Nos. 5,208,036, 5,264,618, 5,279,833 and 5,283,185. The liposomes may be constructed to contain a targeting moiety or ligand, such as an antigen, an antibody, or a virus on their surface to facilitate delivery to the appropriate tissue. The liposomes may also be surface-coated, e.g., by incorporation of phospholipid-polyethyleneglycol conjugates, to extend blood circulation time and allow for greater targeting via the bloodstream.

[0117] Receptor-mediated endocytic pathways for the uptake of DNA may permit the targeted delivery of genes to specific cell types *in vivo*. Receptor-mediated methods of gene transfer involve the generation of complexes between plasmid DNA and specific polypeptide ligands (Wu, G. Y., J. Biol. Chem. 266:14338 (1991) that can be recognized by receptors on the cell surface. One of the problems with receptor-mediated uptake for gene delivery is that the endocytic vesicles formed during this process may be transported to the lysosome, where the contents of the endosome are degraded. Methods have been developed to facilitate escape of the DNA from the endosome during the course of its transport. For example, either whole adenovirus (Wagner, E. *et al.*, Proc. Natl. Acad. Sci. U.S.A. 89:6099 (1992) or fusogenic peptides of the

influenza HA gene product (Wagner, E., *et al.*, Proc. Natl. Acad. Sci. U.S.A. 89:7934 (1992) may be used to induce efficient disruption of DNA-containing endosomes.

[0118] In cases such as those outlined above, where a vector may be targeted to selectively transfect a specific population of cells, it will be understood that in addition to local administration (such as may be achieved by injection into the target tissue), the vector may be administered systemically (e.g., intravenously) in a biologically-compatible solution or pharmaceutically acceptable delivery vehicle. Vector constructs administered in this way may selectively infect the target tissue or may be designed to be selectively expressed in a target tissue (e.g., by way of a tissue-specific promoter).

[0119] A variety of mammalian expression vectors may be used to express ATF6 in mammalian cells. Commercially available mammalian expression vectors which may be suitable include, but are not limited to, pMCIneo (Stratagene), pXTI (Stratagene), pSG5 (Stratagene), EBO-pSV2-neo (ATCC 37593) pBPV-1(8-2) (ATCC 37110), pdBPV-MMTneo(342-12) (ATCC 37224), pRSVgpt (ATCC 37199), pRSVneo (ATCC 37198), pSV2-dhfr (ATCC 37146), pUCTag (ATCC 37460), and IZD35 (ATCC 37565). Other vectors that have been shown to be suitable expression systems in mammalian cells include the herpes simplex viral based vectors: pHSV1 (Geller *et al.*, Proc. Natl. Acad. Sci. USA 87:8950-8954 (1990)); recombinant retroviral vectors: MFG (Jaffee *et al.*, Cancer Res. 53:2221-2226 (1993)); Moloney-based retroviral vectors: LN, LNSX, LNCX, LXSX (Miller and Rosman Biotechniques 7:980-989 (1989)); vaccinia virus vectors: MVA (Sutter and Moss Proc. Natl. Acad. Sci. 89:10847-10851 (1992)); recombinant adenovirus vectors : pJM17 (Ali *et al.*,

Gene Therapy 1:367-384 (1994)), (Berkner K. L. Blotechniques 6:616-624 (1988)); second generation adenovirus vectors: DE1/DE4 adenoviral vectors (Wang and Finer, Nature Medicine 2:714-716 (1996) ); and adeno-associated viral vectors: AAV/Neo (Muro-Cacho *et al.*, J. Immunotherapy 11:231-237 (1992)). Other gene therapy vectors are disclosed, for example, by Teiger *et al.*, Biomed. Pharmacother. 55:148-54 (2001), and by Buchschacher *et al.*, Hum Gene Ther. 12:1013-19 (2001). Preparation of custom vectors based on any appropriate vector known in the art is also within the scope of the present invention.

[0120] Delivery of expression vectors to brain tissue has been described in several publications. For example, U.S. Patent Nos. 4,866,042, 5,082,670, and 5,529,774, herein incorporated by reference, disclose the use of grafts or implants as one mechanism for introducing retroviral vectors bearing therapeutic gene sequences into the brain. These patents also describe an approach in which the vectors are transmitted across the blood brain barrier. Examples of viral vectors that can be used in the delivery of nucleic acids to the brain according to the invention include herpes simplex virus (HSV) vectors, adenovirus vectors, adeno-associated virus (AAV) vectors, and lentivirus vectors. As an example, WO 98/46273 describes gene delivery using an adeno-associated viral vector that is administered to the brain using a syringe or a catheter. WO 98/46273 also discloses intraventricular delivery in order to obtain widespread, global delivery throughout the brain.

[0121] Use of agents that enhance nucleic acid delivery to the brain is also contemplated as part of the invention. For example, intraparenchymal

penetration may be enhanced by lowering brain interstitial pressure using systemic mannitol. *See, e.g.*, PCT Patent Application No. WO 98/46273.

[0122] Alternate approaches to brain delivery of nucleic acids include injection of naked plasmid DNA as well as liposome-nucleic acid complexes. Suitable lipids and related analogs are described by U.S. Patent Nos. 5,208,036, 5,264,618, 5,279,833 and 5,283,185. Vectors and DNA encoding an agent can also be adsorbed to or associated with particulate carriers, examples of which include polymethyl methacrylate polymers and polylactides and poly(lactide-coglycolides). *See, e.g.*, McGee *et al.*, J. Micro Encap. (1996).

[0123] The nucleic acid vectors of the invention described above may also comprise transcription regulatory sequences such as promoters, enhancers, activators, repressors, terminators, and the like. A promoter may be such that, for example, ATF6 is constitutively expressed or, alternatively, one in which expression is inducible. That is, the promoter may respond to a cellular signal that is always present or to a signal that is only present under certain environmental conditions. As mentioned earlier, examples of promoters that cause expression in the brain include the platelet-derived growth factor (PDGF) promoter (WO 02/26936); prion promoter (Hsiao *et al.*, Science 274:99-102 (1996); and the neuron-specific enolase promoter (Xu R., *et al.*, Gene Ther. 8(17):1323-32 (2001). Examples of promoter/enhancers systems used for the expression of genes in neuronal cells include the promoter/enhancer from the immediate early (IE) human cytomegalovirus (hCMV) (WO 98/46273 and WO 99/50404), and the promoter/enhancer from the human neurofilament-light (hNF-L) gene (Vidal-Sanz M., *et al.*, Eur J Neurosci. 3(8):758-763 (1991). Examples of terminators used in mammalian systems include those from the

cytomegalovirus and SV40 systems, as well as the bovine growth hormone (BGH) polyadenylation sequence. See, *e.g.*, WO 98/55616, WO 02/16594 and U.S. Patent Nos. 6,248,555 and 6,323,030.

### **Functional forms of ATF6**

[0124] ATF6 is a transmembrane transcription factor having a cytosolic N-terminal domain (about 370-380 amino acids long), a 21-residue transmembrane domain, and a 270-residue extracytoplasmic domain that projects into the ER lumen. Upon activation, for example, in response to the accumulation of unfolded proteins in the ER, ATF6 is cleaved to release the N-terminal domain.

[0125] Therefore, a nucleic acid sequence encoding a functional form of ATF6 may encode the full-length form of ATF6, the N-terminal domain of ATF6, and/or a functional derivative of either the full-length or the N-terminal domain of ATF6.

[0126] Site-1 protease (S1P) and site-2 protease (S2P) are involved in the cleavage of ATF6 to release the N-terminal domain into the cytosol. Ye et al (2000) discloses the location of amino acids where cleavage of ATF6 may occur, including the proposed location of the transmembrane domain. Therefore, the N-terminal domain of ATF6 may include polypeptide chains that start at amino acid no. 1 and end at any of the amino acids that are part of the transmembrane domain. That is, the N-terminal domain of ATF6 may be a polypeptide chain starting at amino acid no. 1 and ending at any residue from amino acid no. 378 to amino acid no. 398. For example, the N-terminal domain of ATF6 may end at those amino acids where enzymatic cleavage by S1P or S2P occurs. A nucleic acid sequence encoding the desired N-

terminus amino acid sequence of ATF6 may be prepared by recombinant techniques known in the art.

[0127] Additionally, a nucleotide sequence comprising the bZIP domain of ATF6 is also considered a functional form of ATF6. This statement is based on the discovery by Wang *et al.* that a peptide comprising the bZIP domain of ATF6 was able to bind an ATF6 consensus DNA sequence and presumably activate transcription of UPR-regulated genes. Wang *et al.*, J. Biol. Chem. 275:27013-27020 (2000).

[0128] Derivatives of either the full-length ATF6, the N-terminal domain of ATF6, or a peptide comprising the bZIP domain of ATF6 (hereinafter derivatives of ATF6) may be produced by techniques known in the art, including, but not limited to, deletions, additions, conservative amino acid substitutions, or other manipulations that produce a molecule that maintains the property of preventing of cell-death when overexpressed.

[0129] Ample evidence demonstrates that derivatives of natural proteins often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers conducted extensive mutational analysis of human cytokine IL-1a. Gayle *et al.* J. Biol. Chem. 268:22105-22111 (1993). They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either (binding or biological activity)." In fact, only, 23 unique amino acid sequences, out of more than 3,500

nucleotide sequences examined, produced a protein that significantly differed in activity from that of the wild-type.

[0130] Guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie *et al.*, "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," Science 247:1306-1310 (1990). The authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

[0131] The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection are likely positions that are not critical for protein function. Thus, positions that tolerate amino acid substitution could be modified while still maintaining biological activity of the protein.

[0132] The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis by alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) may be used. Cunningham and Wells, Science 244:1081-1085 (1989).

[0133] Bowie *et al.*, Science 247:1306-1310 (1990), indicate that these two strategies have shown that proteins are surprisingly tolerant of amino acid substitutions. The authors further disclose which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most

buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved.

[0134] In general, amino acid substitutions made in order to prepare derivatives of ATF6 are accomplished by selecting substitutions that do not differ significantly in their effect on maintaining, for example, (a) the structure of the ATF6 peptide backbone in the area of the substitution, (b) the charge or hydrophobicity of ATF6 at the target site, or (c) the bulk of a side chain. Naturally occurring residues are divided into groups based on common side-chain properties, for example:

- (1) hydrophobic: norleucine, met, ala, val, leu, ile;
- (2) neutral hydrophilic: cys, ser, thr;
- (3) acidic: asp, glu;
- (4) basic: asn, gln, his, lys, arg;
- (5) residues that influence chain orientation: gly, pro; and
- (6) aromatic; trp, tyr, phe.

[0135] Therefore, conservative amino acid substitutions include, for example, substitution of an aspartic acid residue by a glutamic acid residue because both are acidic amino acids. Similarly, the following examples show acceptable conservative substitutions: lysine/arginine/histidine as basic amino acids; leucine/isoleucine, methionine/valine, alanine/valine as hydrophobic amino acids; serine/glycine/alanine/threonine as hydrophilic amino acids.

[0136] Conservative amino acid substitutions also include groupings based on side chains. For example, substitutions include substitutions among amino acids that belong to a group having aliphatic side chains, such as glycine, alanine,

valine, leucine, and isoleucine. Similarly, substitutions among a group of amino acids having aliphatic-hydroxyl side chains include substitutions between serine and threonine; substitutions among a group of amino acids of amide-containing side chains include substitutions between asparagine and glutamine; substitutions among a group of amino acids having aromatic side chains include substitutions between phenylalanine, tyrosine, and tryptophan; substitutions among a group of amino acids having basic side chains include substitutions between lysine, arginine, and histidine; and substitutions among a group of amino acids having sulfur-containing side chains include substitutions between cysteine and methionine.

[0137] Therefore, one skilled in the art can predict based on these guidelines that replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid will not have a major effect on the properties of the resulting ATF6 derivative.

[0138] Additionally, computer programs that predict the effect of a specific amino acid substitution or mutation on the structure of the protein are available. PCT Patent Application No. WO 02/543063 discloses one such method and also reviews the state of the art in this field.

[0139] Whether any amino acid change (deletion, addition, substitution, or a combination thereof) results in a functional ATF6 derivative can readily be determined by assaying the cell-death prevention activity of the derivative.

[0140] In addition to conservative amino acid substitutions, ATF6 derivatives used in the instant invention include (i) substitutions with one or more non-conserved amino acid residues, where the substituted amino acid residue may be a

chemically modified amino acid (e.g., by methylation, acylation, etc.) that may or may not be encoded by the genetic code, (ii) substitutions with one or more amino acid residues having a substituent group, (iii) fusion of AFT6 with another compound, such as a compound to increase the stability and/or solubility of ATF6 (for example, polyethylene glycol), or (iv) fusion of the AFT6 polypeptide with additional amino acids. Examples of preparation of derivatives following these guidelines can be found in, for example, U.S. Patent No. 5,876,969, EP Patent 0 413 622, and U.S. Patent No. 5,766,883. Such derivatives of ATF6 may be administered directly to a cell or subject instead of administering a nucleic acid encoding for a derivative of ATF6.

[0141] Derivatives of ATF6 that contain deletions or additions of amino acid residues may be produced by using known methods of protein engineering and recombinant DNA technology. For instance, one or more amino acids can be deleted or added from either the N-terminus or C-terminus of ATF6 (or both terminus) without substantial loss of biological function.

[0142] For example, Ron and coworkers reported variant keratinocyte growth factor (KGF) proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Ron *et al.* J. Biol. Chem. 268:2984-2988 (1993). Similarly, interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of the protein. Dobeli *et al.*, J. Biotechnol. 7:199-216 (1988).

[0143] Additionally, derivatives of ATF6 may be prepared by modification of the amino acids in ATF6 or in a derivative of ATF6. Modifications may occur anywhere in ATF6 or its derivative, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. Modifications may

include, for example, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of other functional moiety, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formylation, gamma-carboxylation, glycosylation, glycosylphosphatidylinositol (GPI) anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. See, for instance, E. Creighton *Proteins—Structure and Molecular Properties*, 2nd Ed., W. H. Freeman and Company, New York (1993); B. C. Johnson, *Post Translational Covalent Modification of Proteins*, Academic Press, New York, (1983); Seifter *et al.*, *Meth. Enzymol.* 182:626-646 (1990); Rattan *et al.*, *Ann. N.Y. Acad. Sci.* 663:48-62 (1992). Preparation of these modified derivatives may, for example, be useful if direct administration of the derivative, rather than administration of a nucleic acid encoding the derivative, is contemplated.

[0144] Because of the degeneracy of genetic code, the skilled artisan may prepare more than one nucleic acid sequence that encodes ATF6 or one of its derivatives. Administration of nucleic acids obtained in this manner is also encompassed by the instant invention.

[0145] Use of natural and non-natural allelic variations of ATF6 is also contemplated as being part of the invention. These allelic variants can vary at either the polynucleotide and/or polypeptide level. Non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis. Therefore,

the present invention is also directed to proteins containing polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the ATF6 polypeptide sequences shown in Figures 1-4. The methods of the invention may also utilize nucleic acid molecules comprising, or alternatively, consisting of, a polynucleotide sequence at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the polynucleotide sequence encoding ATF6. Whether any particular nucleic acid molecule or polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to an ATF6 sequence can be determined conventionally using known computer programs. See, *e.g.*, WO 01/54474.

[0146] Nucleic acids encoding these homologous polynucleotide sequences can be isolated by hybridization under different conditions. It is well known in the art that the degree of stringency (high, intermediate, low, etc.) depends on factors such as the length and nature of the sequence (DNA, RNA, base composition), nature of the target (DNA, RNA, base composition), milieu (in solution or immobilized on a solid substrate), concentration of salts and other components (*e.g.*, formamide, dextran sulfate and/or polyethylene glycol), and temperature of the reactions (within a range from about 5°C below the melting temperature of the probe to about 20°C to 25°C below the melting temperature). Functionally, maximum stringency conditions may be used to identify nucleic acid sequences having strict identity or near-strict identity with the hybridization probe; while high stringency conditions may be used to identify nucleic acid sequences having about 80% or more sequence identity with the probe. Persons skilled in the art will appreciate that one or more factors be may be varied to generate conditions of stringency that may be

different from each other in temperature and ionic strength composition but that are equivalent to in terms of the results desired. One general guide for nucleic acid hybridization is Tijssen, "Laboratory Techniques in Biochemistry and Molecular Biology" Elsevier, vol.24, Hybridization with Nucleic Acid Probes, Part I Overview of principles of hybridization and the strategy of nucleic acid assays (1993).

[0147] Whether any homologous polynucleotide sequence encodes a functional ATF6 derivative can readily be determined by assaying the cell-death prevention activity of the derivative.

#### **Inducing expression of UPR-regulated genes**

[0148] As mentioned previously, ATF6 acts as a transcription factor and binds to the ERSE, thereby inducing the expression of UPR-responsive genes. As expected, however, other basal transcription factors are required before transcription of these genes can occur. Some of these basal transcription factors include NF-Y and YY1. van Laar *et al.*, Current Protein and Peptide Science 2:169-190 (2001).

[0149] Therefore, in one embodiment of the present invention the method for preventing cell death may comprise introducing a vector comprising a nucleic acid sequence encoding a basal transcription factor that binds to the ERSE. For example, the vector may comprise a nucleic acid sequence encoding NF-Y, YY1, or both. Furthermore, the vector may optionally comprise a nucleic acid sequence encoding ATF6.

[0150] Furthermore, a method for preventing cell death may comprise any known method in the art that induces the expression of endogenous ATF6. For example, a method for inducing the expression of ATF6 may include inducing

the UPR. This induction may take place by the accumulation of unfolded proteins in the ER or by inducing the execution of any intermediate step in the signaling pathway between the accumulation of unfolded proteins in the ER and the expression of ATF6.

[0151] In mammalian cells, one such intermediate step includes the activation of the transmembrane kinase Ire1, of which two isoforms have been identified (activation of Ire1 is induced by the accumulation of unfolded proteins in the ER). van Laar *et al.*, Current Protein and Peptide Science 2:169-190 (2001). Activation of Ire1 involves dimerization and autophosphorylation, after which presenilin 1 and 2 cleave the kinase-nuclease domain of Ire1. This cleavage occurs in a RIP-like fashion analogous to the release of the N-terminus of ATF6 after cleavage by SP1 and/or SP2.

[0152] Although ATF6 may be activated by an Ire1-independent mechanism induced only by accumulation of unfolded proteins in the ER, active ATF6 may also be produced by an Ire1-catalyzed splicing of ATF6 mRNA that results in a fragment encoding only the soluble domain of ATF6. van Laar *et al.*, Current Protein and Peptide Science 2:169-190 (2001), hereby incorporated by reference in its entirety.

[0153] Therefore, a method for inducing the expression of ATF6 may comprise, for example, introducing into a cell a vector comprising a nucleic acid sequence encoding one of more of the following molecules: any one of the transmembrane isoforms of Ire1, any soluble form of Ire1, presenilin 1, and/or presenilin 2.

[0154] Additionally, a method for inducing the expression of ATF6 may also comprise introducing into a cell a vector comprising a nucleic acid sequence encoding

one of more transcription factors for any of the following genes: any one of the transmembrane isoforms of Ire1, any soluble form of Ire1, presenilin 1, presenilin 2 and ATF6.

[0155] Furthermore, because processing of ATF6 occurs via proteolysis by S1P and/or S2P, another method for inducing the expression of ATF6 may comprise introducing into a cell a vector comprising a nucleic acid sequence encoding S1P, S2P, or both, wherein this vector optionally comprises a nucleic acid sequence encoding ATF6.

[0156] Alternatively, induction of ATF6 may also be effected by exposing the host cell to suitable environmental conditions. An example of these conditions include incubation of cell in the presence of tunicamycin, or in the presence of any other inhibitor of protein folding known in the art.

#### **Homologous and nonhomologous recombination**

[0157] Because the original endogenous promoter activates transcription of the ATF6 gene only under conditions that trigger the UPR, it may be advantageous to replace this promoter with a promoter that allows constitutive expression of the ATF6 gene or at least enhanced expression with respect to the endogenous expression. Therefore, in one embodiment of the invention the promoter sequence of ATF6 is targeted for replacement by a nucleic acid sequence comprising an exogenous promoter sequence (not the original promoter).

[0158] The nucleic acid sequence to be inserted by homologous recombination may comprise a promoter flanked by two targeting regions of sufficient length. These targeting regions comprise nucleotide sequences flanking the

endogenous promoter of ATF6. A sufficient length for each targeting region sequence is normally between 50-200 bp, although the skilled artisan will recognize that other lengths may also be used successfully. The exogenous promoter may be, for example, the human cytomegalovirus (CMV) enhancer/promoter.

[0159] In addition to using sequences unique to the target region, the skilled artisan may also use sequences that are homologous to repetitive sequences found in the mammalian genome, such as the Alu, LINE, THE, etc., sequences. See, e.g., U.S. Patent No. 6,015,708. These sequences may be present one or multiple times on the targeting region sequence flanking the nucleic acid sequence to be inserted by homologous recombination.

[0160] In another embodiment of the invention, the endogenous gene encoding ATF6 and the corresponding promoter in a cell are replaced by a nucleic acid sequence encoding one or more copies of an ATF6 gene (e.g., either the full length or soluble domains) placed under the control of a exogenous promoter, for example the human cytomegalovirus (CMV) enhancer/promoter. Optionally, the nucleic acid sequence may also comprise sequences coding for S1P, S2P, or both. As mentioned previously in a similar context, these nucleic acid sequences may contain additional transcriptional regulatory sequences that modify the expression of the gene of interest such as, for example, by increasing the rate of transcription, increasing translation efficiency, increasing mRNA accumulation, making the expression inducible, etc.

[0161] The nucleic acid sequence to be inserted by homologous recombination may optionally include at least one selectable marker gene, such as a gene

providing a particular antibiotic resistance. Furthermore, the nucleic acid sequence to be inserted by homologous recombination may include an amplifiable gene, which may also allow amplification of the gene of interest. Amplifiable genes include dihydrofolate reductase (DHFR, metallothionein-I and -II, for example of primate origin, adenosine deaminase, ornithine decarboxylase, glutamate synthase, etc. In some cases, the selectable marker and the amplifiable marker may be the same.

[0162] In another embodiment of the invention, the nucleic acid sequence encoding one or more copies of an ATF6 gene and suitable transcriptional regulatory sequences does not replace the endogenous ATF6 gene, but is inserted at a different region in the genome. In this case, the nucleic acid sequence includes two targeting segments, which, while separated from one another in the sequence by those elements to be inserted into the genome, may be contiguous in the native genome. The skilled artisan will recognize that there is no criticality as to the specific location of the inserted nucleic acid sequence within the genome. It is only important that it be taken up somewhere within the nucleus because both the regulatory segment or segments and the exogenous gene (as well as any selectable markers and amplifiable genes) are inserted together. Homologous recombination is described, for example, in U.S. Patent Nos. 5,282,071, and 5,578,461.

[0163] In another embodiment of the invention, a nucleic acid sequence encoding one or more copies of an ATF6 gene and suitable transcriptional regulatory sequences is introduced into a cell by nonhomologous or nontargeted recombination. That is, the nucleic acid sequences in this embodiment of the invention do not contain target sequences. In most cases, nonhomologous

recombination is thought to occur through the joining of free nucleic acid ends that contain an end capable of being joined to a second nucleic acid end, either directly, or following repair or processing. The nucleic acid end may consist of a 5' overhang, a 3' overhang, or blunt end. As mentioned previously, these nucleic acid sequences may optionally comprise sequences coding for S1P, S2P, a selectable marker, or an amplifiable marker.

[0164] As with homologous recombination of nucleic acid sequences comprising both the regulatory segment or segments and the exogenous gene (as well as any selectable markers and amplifiable genes), the skilled artisan will recognize that there is no criticality as to the specific location of the inserted nucleic acid sequence within the cell. Nonhomologous recombination is described, for example, in PCT Application No. WO 00/49162.

[0165] The techniques of homologous and nonhomologous recombination may be used to introduce, into a cell, nucleotide sequences encoding any of the molecules expressly mentioned in this application or any other molecule that would be apparent to the skilled artisan as being useful in the methods of the instant invention upon reading the instant application as a whole.

[0166] Although some embodiments of the invention have been described in terms of introducing into a cell a vector comprising a nucleic acid sequence encoding a particular molecule, the methods of the invention also contemplate the introduction of a vector comprising a nucleic acid sequence encoding a functional derivative of that molecule, or any other molecule that would be apparent to the skilled artisan as useful in the methods of the instant invention upon reading the application as a whole.

[0167] Additionally, the present invention also contemplates combination in a single embodiment of one or more of the methods described throughout the specification for the purpose of preventing cell death.

### **Compositions**

[0168] The present invention also provides compositions useful in carrying out the methods of the invention.

[0169] These compositions may contain an agent in ranges from about 0.1 to about 10% of the composition. In another embodiment, these compositions may contain an agent in ranges from about 0.5 to about 5% of the composition. In yet another embodiment, these compositions may contain an agent in ranges from about 1 to about 3% of the composition. An agent in the context of the compositions of the invention is any molecule (nucleic acid sequence, protein, etc.) identified in this application as useful in the methods of the instant invention.

[0170] The compositions of the invention may also be used in appropriate association with other pharmaceutically active compounds. The following methods and excipients are merely exemplary and are in no way meant to be limiting.

[0171] For oral compositions, the agents can be used alone or in combination with appropriate additives to make tablets, powders, granules or capsules, for example, with conventional additives, such as lactose, mannitol, corn starch or potato starch; with binders, such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins; with disintegrators, such as corn starch, potato starch or sodium carboxymethylcellulose; with lubricants, such

as talc or magnesium stearate; and if desired, with diluents, buffering agents, moistening agents, preservatives, and flavoring agents.

[0172] The compositions may include, depending on the composition desired, pharmaceutically acceptable, nontoxic carriers or diluents, which are defined as vehicles commonly used to formulate compositions for animal or human administration. The diluent is selected so as not to affect the biological activity of the combination. Examples of such diluents are distilled water, physiological phosphate-buffered saline, Ringer's solutions, dextrose solution, and Hank's solution. In addition, the composition may also include other carriers, adjuvants, or nontoxic, nontherapeutic, nonimmunogenic stabilizers and the like. Also included may be carrier molecules such as proteoglycans. Specific examples of such carrier molecules include, but are not limited to, glycosaminoglycans such as heparin sulfate, hyaluronic acid, keratin-sulfate, chondroitin 4-sulfate, chondroitin 6-sulfate, heparin sulfate and dermatin sulfate, perlecan, and pento polysulfate.

[0173] The agents of the invention may be formulated into preparations for injection by dissolving, suspending, or emulsifying the agent in a physiologically acceptable diluent with a carrier. Carriers include sterile liquids, such as water, oils, with or without the addition of a surfactant, and glycols. Oils may be petroleum derivatives, or of animal, vegetable, and synthetic origin, for example, peanut oil, soybean oil, and mineral oil. Examples of glycols include propylene glycol and polyethylene glycol. The compositions may also contain conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preservatives. The agents of this invention may also be used in a sustained release form, for example a depot

injection, implant preparation, or osmotic pump, which can be formulated in such a manner as to permit a sustained release of the active ingredient.

[0174] The agents can be utilized in an aerosol composition to be administered via inhalation or pulmonary delivery. The agents of the present invention may be formulated into pressurized acceptable propellants such as dichlorodifluoromethane, nitrogen, and the like.

[0175] Administration of an agent of the invention may be accomplished by any convenient means, including parenteral injection, and may be systemic or localized in delivery. The agents of this invention can be incorporated into a variety of compositions for therapeutic administration. In general, the agents of the present invention can be formulated into compositions by combination with appropriate pharmaceutically acceptable carriers or diluents, and may be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants, gels, microspheres, and aerosols. As such, administration of the agents can be achieved in various ways, including oral, buccal, rectal, parenteral, intraperitoneal, intradermal, transdermal, intratracheal, intrathecal, intranasal, gastric, intramuscular, intracranial, subdermal, etc., administration. The active agent may be systemic after administration or may be localized by the use of regional administration, intramural administration, or use of an implant that acts to retain the active component at the site of implantation.

[0176] Unit dosage forms for oral or rectal administration such as syrups, elixirs, and suspensions may be provided wherein each dosage unit, for example, teaspoonful, tablespoonful, tablet, or suppository, contains a predetermined

amount of the composition containing one or more agents of the present invention. Similarly, unit dosage forms for injection or intravenous administration may comprise the agent of the present invention in a composition as a solution in sterile water, normal saline, or another pharmaceutically acceptable carrier.

[0177] Doses for nucleic acids encoding other agents of the invention range from about 10 ng to about 1 g, from about 100 ng to about 100 mg, from about 1  $\mu$ g to about 10 mg, or from about 30 to about 300  $\mu$ g DNA per subject. Doses for infectious viral vectors vary from about 10 to about 100, or more, virions per dose.

[0178] Those of skill in the art will readily appreciate that dose levels can vary as a function of the specific agent, the severity of the symptoms, and the susceptibility of the subject to side effects. Additionally, some of the specific agents of the invention may be more potent than others. Dosages for a given agent are readily determinable by those of skill in the art by a variety of means, for example by measuring the relative physiological potency of a given agent by methods known in the art with respect to the potency of another agent and adjusting the dosage accordingly.

[0179] Implants for sustained release compositions are well-known in the art.

Implants are formulated as microspheres, slabs, etc. with biodegradable or non-biodegradable polymers. For example, polymers of lactic acid and/or glycolic acid form an erodible polymer that is well-tolerated by the host. The implant is, for example, placed in proximity to the site of protein deposits (e.g., the site of formation of protein deposits associated with neurodegenerative

disorders), so that the local concentration of active agent is increased at that site relative to the rest of the body.

[0180] The compositions can also be administered by infusion into the brain, and may be administered in either a continuous (e.g., sustained) or non-continuous fashion. Methods, compositions, and devices suitable for delivery to the brain in a continuous (e.g., chronic) or non-continuous (e.g., single, discrete dose per administration) fashion are described in, for example, U.S. Patent Nos. 5,711,316; 5,832,932; 5,814,014; 5,782,798; 5,752,515; 5,735,814; 5,713,923; 5,686,416; 5,624,898; 5,624,894; 5,124,146; and 4,866,042.

[0181] A typical dosage unit for administration to a subject includes, but is not limited to: a solution suitable for intravenous administration; a tablet taken from two to six times daily; or a time-release capsule or tablet taken once a day and containing a proportionally higher content of active ingredient, etc. The time-release effect may be obtained by capsule materials that dissolve at different pH values, by capsules that release slowly by osmotic pressure, or by any other known means of controlled release.

### **Screening Method**

[0182] The present invention also provides for a method to screen for substances that affect ATF6 activity.

[0183] In one embodiment, the method can determine whether a substance increases or decreases the activity of at least one functional form of ATF6 in a cell whose production by a cell evokes a responsive change in at least one

characteristic. This method can comprise providing two cell lines, one which produces at least one functional form of ATF6 and a second which produces the at least one functional form of ATF6 at a lower level than the first cell line, or does not produce the at least one functional form of ATF6 at all. Then, the substance can be placed in contact with the first and second cell lines.

Finally, one can compare the at least one characteristic of the first cell line with the second cell line.

[0184] In exemplary embodiments, the first and second cell lines are neurons or nigral neurons.

[0185] In exemplary embodiments, the at least one characteristic is chosen from a characteristic that is observable with the naked eye, a characteristic that is a cultural characteristic of the cell, a characteristic that is a morphological characteristic, and combinations thereof. Additionally, the at least one characteristic can be a measure of an amount of ATF6 mRNA, or a measure of an amount of at least one functional form of ATF6 protein.

[0186] In other exemplary embodiments, the at least one characteristic can be a rate of cell death, a rate of cell proliferation, or combinations thereof.

[0187] In other exemplary embodiments, the at least one characteristic can be a response along the UPR signaling pathway. This response can be an expression of a gene chosen from Ire1, presenilin 1, presenilin 2, ATF6 regulated genes, or combination thereof.

[0188] In other exemplary embodiments, the at least one characteristic can be an expression of a UDR-regulated gene. The UDR-regulated gene can be a molecular chaperone BiP gene, a gene involved in protein glycosylation, a

gene involved in protein secretion, a gene involved in protein degradation, a gene involved in membrane biosynthesis, or combinations thereof.

[0189] In other exemplary embodiments, the characteristic can be a cleavage rate of a full length ATF6, a rate of protein folding, a measure of an amount of protein accumulation, a measure of an amount of protein aggregation, a measure of an amount of protein precipitation, a measure of an amount of protein plaques, or combinations thereof.

[0190] Additionally, the present invention also contemplates other methods of screening which are combinations of those mentioned above, or are implied in the previously-described other embodiments of the invention.

[0191] Please incorporate the paper copy of the sequence listing at the end of the specification.

We claim:

1. A method for preventing cell death in a subject in need thereof comprising, administering to the subject an effective amount of a composition comprising a nucleic acid encoding at least one functional form of ATF6.
2. The method according to claim 1, whereby the at least one functional form of ATF6 is chosen from a full-length form of ATF6, an N-terminal domain form of ATF6, a bZIP-ATF6 fragment, functional derivatives thereof, and combinations thereof.
3. The method according to claim 2, whereby the full-length form of ATF6 is chosen from human ATF6- $\alpha$ , human ATF6- $\beta$ , murine ATF6- $\alpha$ , and murine ATF6- $\beta$ .
4. The method according to claim 1, whereby the at least one functional form of ATF6 is a full-length form of ATF6 or an N-terminal domain form of ATF6 having at least one modification chosen from deletions, additions, amino acid substitutions, conservative amino acid substitutions, and combinations thereof.
5. The method according to claim 1, whereby the nucleic acid further comprises a nucleic acid sequence encoding at least one basal transcription factor that binds to the ER-stress responsive element.
6. The method according to claim 5, whereby the at least one basal transcription factor is chosen from NF-Y, YY1, functional derivatives thereof, and combinations thereof.
7. The method according to claim 1, whereby the nucleic acid further comprises at least one transcriptional regulatory sequence.

8. The method according to claim 7, whereby the at least one transcriptional regulatory sequence is chosen from promoters, enhancers, activators, terminators, polyadenylation signals, and combinations thereof.

9. The method according to claim 1, whereby the nucleic acid further comprises a nucleic acid sequence that induces expression of a functional form of ATF6.

10. The method according to claim 9, whereby the nucleic acid sequence that induces expression of a functional form of ATF6 is chosen from Ire1, presenilin 1, preselinin 2, transcription factors of ATF6, site-1 protease, site-2 protease, promoters that replace the original promoter of the gene encoding ATF6 in the cell's genome, enhancers that replace the original promoter of the gene encoding ATF6 in the cell's genome, and combinations thereof.

11. The method according to claim 1, whereby the administering is used as a stand-alone therapy.

12. The method according to claim 1, whereby the nucleic acid further comprises a vector chosen from viral vectors, plasmids, and cosmids.

13. The method according to claim 12, whereby the vector is a mammalian vector.

14. The method according to claim 12, whereby the vector directs nucleic acid delivery to the brain.

15. The method according to claim 12, whereby the vector is chosen from neural-specific expression vectors, blood brain barrier transmission-specific vectors, vectors comprising a neural-specific promoter, and combinations thereof.

16. The method according to claim 12, whereby the vector is chosen from retroviruses, adeno-associated viruses, herpes viruses, vaccinia viruses, RNA viruses, herpes simplex virus vectors, adenovirus vectors, adeno-associated virus vectors, lentivirus vectors, vectors comprising a platelet-derived growth factor promoter, vectors comprising a prion promoter, vectors comprising a neuron-specific enolase promoter, vectors comprising promoter/enhancer systems from an immediate early human cytomegalovirus, vectors comprising promoter/enhancer systems from a human neurofilament-light gene, vectors comprising terminators from a cytomegalovirus system, vectors comprising terminators from an SV40 system, and vectors comprising terminators from a bovine growth hormone polyadenylation sequence.

17. The method according to claim 1, whereby the composition further comprises at least one agent that enhances nucleic acid delivery to the brain.

18. The method according to claim 17, whereby the at least one agent that enhances nucleic acid delivery to the brain is mannitol.

19. The method according to claim 1, whereby the composition further comprises at least one pharmaceutically acceptable additive, lubricant, diluent, buffer, moistening agent, preservative agent, flavoring, adjuvant, carrier, stabilizer, suspending agent, emulsifying agent, propellant, or other vehicle.

20. A method for preventing cell death in a cell in need thereof comprising, administering to the cell an effective amount of a composition comprising a nucleic acid encoding at least one functional form of ATF6.

21. The method according to claim 20, whereby the at least one functional form of ATF6 is chosen from a full-length form of ATF6, an N-terminal domain form of ATF6, a bZIP-ATF6 fragment, functional derivatives thereof, and combinations thereof.

22. The method according to claim 21, whereby the full-length form of ATF6 is chosen from human ATF6- $\alpha$ , human ATF6- $\beta$ , murine ATF6- $\alpha$ , and murine ATF6- $\beta$ .

23. The method according to claim 20, whereby the at least one functional form of ATF6 is a full-length form of ATF6 or an N-terminal domain form of ATF6 having at least one modification chosen from deletions, additions, amino acid substitutions, conservative amino acid substitutions, and combinations thereof.

24. The method according to claim 20, whereby the nucleic acid further comprises a nucleic acid sequence encoding at least one basal transcription factor that binds to the ER-stress responsive element.

25. The method according to claim 24, whereby the at least one basal transcription factor is chosen from NF-Y, YY1, functional derivatives thereof, and combinations thereof.

26. The method according to claim 20, whereby the nucleic acid further comprises at least one transcriptional regulatory sequence.

27. The method according to claim 26, whereby the at least one transcriptional regulatory sequence is chosen from promoters, enhancers, activators, terminators, polyadenylation signals, and combinations thereof.

28. The method according to claim 20, whereby the nucleic acid further comprises a nucleic acid sequence that induces expression of a functional form of ATF6.

29. The method according to claim 28, whereby the nucleic acid sequence that induces expression of a functional form of ATF6 is chosen from Irf1, presenilin 1, presenilin 2, transcription factors of ATF6, site-1 protease, site-2 protease, promoters that replace the original promoter of the gene encoding ATF6 in the cell's genome, enhancers that replace the original promoter of the gene encoding ATF6 in the cell's genome, and combinations thereof.

30. The method according to claim 20, whereby the nucleic acid further comprises a vector chosen from viral vectors, plasmids, and cosmids.

31. The method according to claim 30, whereby the vector is a mammalian vector.

32. The method according to claim 30, whereby the vector is chosen from neural-specific expression vectors, blood brain barrier transmission-specific vectors, vectors comprising a neural-specific promoter, and combinations thereof.

33. The method according to claim 30, whereby the vector is chosen from retroviruses, adeno-associated viruses, herpes viruses, vaccinia viruses, RNA viruses, herpes simplex virus vectors, adenovirus vectors, adeno-associated virus vectors, lentivirus vectors, vectors comprising a platelet-derived growth factor promoter, vectors comprising a prion promoter, vectors comprising a neuron-specific enolase promoter, vectors comprising promoter/enhancer systems from an immediate early human cytomegalovirus,

vectors comprising promoter/enhancer systems from a human neurofilament-light gene, vectors comprising terminators from a cytomegalovirus system, vectors comprising terminators from an SV40 system, and vectors comprising terminators from a bovine growth hormone polyadenylation sequence.

34. The method according to claim 20, whereby the composition further comprises at least one pharmaceutically acceptable additive, lubricant, diluent, buffer, moistening agent, preservative agent, flavoring, adjuvant, carrier, stabilizer, suspending agent, emulsifying agent, propellant, or other vehicle.

35. A method for preventing cell death in a subject in need thereof comprising, administering to the subject an effective amount of a composition comprising at least one functional form of ATF6.

36. The method according to claim 35, whereby the at least one functional form of ATF6 is chosen from a full-length form of ATF6, an N-terminal domain form of ATF6, a bZIP-ATF6 fragment functional, derivatives thereof, and combinations thereof.

37. The method according to claim 36, whereby the full-length functional form is chosen from human ATF6- $\alpha$ , human ATF6- $\beta$ , murine ATF6- $\alpha$ , and murine ATF6- $\beta$ .

38. The method according to claim 35, whereby the at least one functional form of ATF6 is a full-length form of ATF6 or an N-terminal domain form of ATF6 having at least one modification chosen from deletions, additions, amino acid substitutions, conservative amino acid substitutions, and combinations thereof.

39. The method according to claim 35, whereby the at least one functional form of ATF6 comprises at least one covalent modification.

40. The method according to claim 39, whereby the at least one modification occurs in at least one region chosen from the peptide backbone, the amino acid side-chains, the amino terminus and the carboxyl terminus.

41. The method according to claim 39, whereby the at least one modification is chosen from acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of a functional moiety, covalent attachment of a lipid, covalent attachment of a lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formylation, gamma-carboxylation, glycosylation, glycosylphosphatidylinositol anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins, arginylation, and ubiquitination.

42. The method according to claim 35, whereby the administering is used as a stand-alone therapy.

43. The method according to claim 35, whereby the composition further comprises at least one pharmaceutically acceptable additive, lubricant, diluent, buffer, moistening agent, preservative agent, flavoring, adjuvant, carrier, stabilizer, suspending agent, emulsifying agent, propellant, or other vehicle.

44. A method for preventing cell death in a cell in need thereof comprising, administering to the cell an effective amount of a composition comprising at least one functional form of ATF6.

45. The method according to claim 44, whereby the at least one functional form of ATF6 is chosen from a full-length form of ATF6, an N-terminal domain form of ATF6, a bZIP-ATF6 fragment, functional derivatives thereof, and combinations thereof.

46. The method according to claim 45, whereby the full-length functional form is chosen from human ATF6- $\alpha$ , human ATF6- $\beta$ , murine ATF6- $\alpha$ , and murine ATF6- $\beta$ .

47. The method according to claim 44, whereby the at least one functional form of ATF6 is a full-length form of ATF6 or an N-terminal domain form of ATF6 having at least one modification chosen from deletions, additions, amino acid substitutions, conservative amino acid substitutions, and combinations thereof.

48. The method according to claim 44, whereby the at least one functional form of ATF6 comprises at least one covalent modification.

49. The method according to claim 48, whereby the at least one modification occurs in at least one region chosen from the peptide backbone, the amino acid side-chains, the amino terminus and the carboxyl terminus.

50. The method according to claim 48, whereby the at least one modification is a from acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of other functional moiety, covalent attachment of a lipid, covalent attachment of a lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation,

demethylation, formation of covalent cross-links, formylation, gamma-carboxylation, glycosylation, glycoposphatidylinositol anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins, arginylation, and ubiquitination.

51. The method according to claim 44, whereby the composition further comprises at least one pharmaceutically acceptable additive, lubricant, diluent, buffer, moistening agent, preservative agent, flavoring, adjuvant, carrier, stabilizer, suspending agent, emulsifying agent, propellant, or other vehicle.

52. A method for preventing cell death in a subject in need thereof comprising, administering to the subject a treatment whereby said treatment induces or suppresses expression of a functional form of ATF6 in an effective amount in the subject.

53. The method according to claim 52, whereby the treatment induces expression a functional form of ATF6.

54. The method according to claim 52, whereby the treatment induces overexpression of a functional form of ATF6.

55. The method according to claim 52, whereby the treatment comprises administering a composition chosen from at least one nucleic acid and at least one protein.

56. The method according to claim 52, whereby the treatment induces expression or overexpression of a functional form of ATF6 by inducing the Unfolded Protein Response.

57. The method according to claim 55, whereby the nucleic acid encodes at least one basal transcription factor that binds to the ER-stress responsive element.

58. The method according to claim 57, whereby the at least one basal transcription factor is chosen from NF-Y, YY1, functional derivatives thereof, and combinations thereof.

59. The method according to claim 55, whereby the nucleic acid comprises at least one transcriptional regulatory sequence.

60. The method according to claim 59, whereby the at least one transcriptional regulatory sequence is chosen from promoters, enhancers, activators, terminators, polyadenylation signals, and combinations thereof.

61. The method according to claim 55, whereby the nucleic acid induces expression of a functional form of ATF6.

62. The method according to claim 61, whereby the nucleic acid sequence that induces expression of a functional form of ATF6 is chosen from Ire1, presenilin 1, preselinin 2, transcription factors of ATF6, site-1 protease, site-2 protease, promoters that replace the original promoter of the gene encoding ATF6 in the cell's genome, enhancers that replace the original promoter of the gene encoding ATF6 in the cell's genome, and combinations thereof.

63. The method according to claim 52, whereby the administering is used as a stand-alone therapy.

64. The method according to claim 55, whereby the nucleic acid comprises a vector chosen from viral vectors, plasmids, and cosmids.

65. The method according to claim 64, whereby the vector is a mammalian vector.

66. The method according to claim 64, whereby the vector directs nucleic acid delivery to the brain.

67. The method according to claim 64, whereby the vector is chosen from neural-specific expression vectors, blood brain barrier transmission-specific vectors, vectors comprising a neural-specific promoter, and combinations thereof.

68. The method according to claim 64, whereby the vector is chosen from retroviruses, adeno-associated viruses, herpes viruses, vaccinia viruses, RNA viruses, herpes simplex virus vectors, adenovirus vectors, adeno-associated virus vectors, lentivirus vectors, vectors comprising a platlet-derived growth factor promoter, vectors comprising a prion promoter, vectors comprising a neuron-specific enolase promoter, vectors comprising promoter/enhancer systems from an immediate early human cytomegalovirus, vectors comprising promoter/enhancer systems from a human neurofilament-light gene, vectors comprising terminators from a cytomegalovirus system, vectors comprising terminators from an SV40 system, and vectors comprising terminators from a bovine growth hormone polyadenylation sequence.

69. The method according to claim 52, whereby the composition further comprises at least one agent that enhances nucleic acid delivery to the brain.

70. The method according to claim 69, whereby the at least one agent that enhances nucleic acid delivery to the brain is mannitol.

71. The method according to claim 52, whereby the composition further comprises at least one pharmaceutically acceptable additive, lubricant, diluent, buffer, moistening agent, preservative agent, flavoring, adjuvant, carrier, stabilizer, suspending agent, emulsifying agent, propellant, or other vehicle.

72. A method for preventing cell death in a cell in need thereof comprising, administering to the subject a treatment whereby said treatment induces or suppresses expression of a functional form of ATF6 in an effective amount in the cell.

73. The method according to claim 72, whereby the treatment induces expression a functional form of ATF6.

74. The method according to claim 72, whereby the treatment induces overexpression of a functional form of ATF6.

75. The method according to claim 72, whereby the treatment comprises administering a composition chosen from at least one nucleic acid and at least one protein.

76. The method according to claim 72, whereby the treatment induces expression or overexpression of a functional form of ATF6 by inducing the Unfolded Protein Response.

77. The method according to claim 75, whereby the nucleic acid encodes at least one basal transcription factor that binds to the ER-stress responsive element.

78. The method according to claim 77, whereby the at least one basal transcription factor is chosen from NF-Y, YY1, functional derivatives thereof, and combinations thereof.

79. The method according to claim 75, whereby the nucleic acid comprises at least one transcriptional regulatory sequence.

80. The method according to claim 79, whereby the at least one transcriptional regulatory sequence is chosen from promoters, enhancers, activators, terminators, polyadenylation signals, and combinations thereof.

81. The method according to claim 75, whereby the nucleic acid comprises a nucleic acid sequence that induces expression of a functional form of ATF6.

82. The method according to claim 81, whereby the nucleic acid sequence that induces expression of a functional form of ATF6 is chosen from Ire1, presenilin 1, preselinin 2, transcription factors of ATF6, site-1 protease, site-2 protease, promoters that replace the original promoter of the gene encoding ATF6 in the cell's genome, enhancers that replace the original promoter of the gene encoding ATF6 in the cell's genome, and combinations thereof.

83. The method according to claim 75, whereby the nucleic acid comprises a vector chosen from viral vectors, plasmids, and cosmids.

84. The method according to claim 83, whereby the vector is a mammalian vector.

85. The method according to claim 83, whereby the vector is chosen from neural-specific expression vectors, blood brain barrier transmission-specific vectors, vectors comprising a neural-specific promoter, and combinations thereof.

86. The method according to claim 83, whereby the vector is chosen from retroviruses, adeno-associated viruses, herpes viruses, vaccinia viruses,

RNA viruses, herpes simplex virus vectors, adenovirus vectors, adeno-associated virus vectors, lentivirus vectors, vectors comprising a platelet-derived growth factor promoter, vectors comprising a prion promoter, vectors comprising a neuron-specific enolase promoter, vectors comprising promoter/enhancer systems from an immediate early human cytomegalovirus, vectors comprising promoter/enhancer systems from a human neurofilament-light gene, vectors comprising terminators from a cytomegalovirus system, vectors comprising terminators from an SV40 system, and vectors comprising terminators from a bovine growth hormone polyadenylation sequence.

87. The method according to claim 72, whereby the composition further comprises at least one pharmaceutically acceptable additive, lubricant, diluent, buffer, moistening agent, preservative agent, flavoring, adjuvant, carrier, stabilizer, suspending agent, emulsifying agent, propellant, or other vehicle.

88. A composition comprising at least one viral vector wherein the at least one viral vector comprises nucleic acid encoding a functional form of ATF6.

89. The composition according to claim 88, wherein the at least one functional form of ATF6 is chosen from a full-length form of ATF6, an N-terminal domain form of ATF6, a bZIP-ATF6 fragment, functional derivatives thereof, and combinations thereof.

90. The composition according to claim 89, wherein the full-length form of ATF6 is chosen from human ATF6- $\alpha$ , human ATF6- $\beta$ , murine ATF6- $\alpha$ , and murine ATF6- $\beta$ .

91. The composition according to claim 88, wherein the at least one functional form of ATF6 is a full-length form of ATF6 or an N-terminal domain form of ATF6 having at least one modification chosen from deletions, additions, amino acid substitutions, conservative amino acid substitutions, and combinations thereof.

92. The composition according to claim 88, wherein the nucleic acid further comprises a nucleic acid sequence encoding at least one basal transcription factor that binds to the ER-stress responsive element.

93. The composition according to claim 92, wherein the at least one basal transcription factor is chosen from NF-Y, YY1, functional derivatives thereof, and combinations thereof.

94. The composition according to claim 88, wherein the nucleic acid further comprises at least one transcriptional regulatory sequence.

95. The composition according to claim 94, wherein the at least one transcriptional regulatory sequence is chosen from promoters, enhancers, activators, terminators, polyadenylation signals, and combinations thereof.

96. The composition according to claim 88, wherein the nucleic acid further comprises a nucleic acid sequence that induces expression of a functional form of ATF6.

97. The composition according to claim 96, wherein the nucleic acid sequence that induces expression of a functional form of ATF6 is chosen from Ire1, presenilin 1, preselinin 2, transcription factors of ATF6, site-1 protease, site-2 protease, promoters that replace the original promoter of the gene encoding ATF6 in the cell's genome, enhancers that replace the original

promoter of the gene encoding ATF6 in the cell's genome, and combinations thereof.

98. The composition according to claim 88, wherein the at least one viral vector is chosen from neural-specific expression vectors, blood brain barrier transmission-specific vectors, vectors comprising a neural-specific promoter, and combinations thereof.

99. The composition according to claim 88, wherein the at least one viral vector is chosen from retroviruses, adeno-associated viruses, herpes viruses, vaccinia viruses, and RNA viruses.

100. The composition according to claim 88, wherein the at least one viral vector directs nucleic acid delivery to the brain.

101. The composition according to claim 88, wherein the at least one viral vector is chosen from neural-specific expression vectors, blood brain barrier transmission-specific vectors, vectors comprising a neural-specific promoter, and combinations thereof.

102. The composition according to claim 88, wherein the at least one viral vector chosen is from retroviruses, adeno-associated viruses, herpes viruses, vaccinia viruses, RNA viruses, herpes simplex virus vectors, adenovirus vectors, adeno-associated virus vectors, lentivirus vectors, vectors comprising a platelet-derived growth factor promoter, vectors comprising a prion promoter, vectors comprising a neuron-specific enolase promoter, vectors comprising promoter/enhancer systems from an immediate early human cytomegalovirus, vectors comprising promoter/enhancer systems from a human neurofilament-light gene, vectors comprising terminators from a cytomegalovirus system, vectors comprising terminators from an SV40

system, and vectors comprising terminators from a bovine growth hormone polyadenylation sequence.

103. The composition according to claim 88, wherein the composition further comprises at least one agent that enhances nucleic acid delivery to the brain.

104. The composition according to claim 103, whereby the at least one agent that enhances nucleic acid delivery to the brain is mannitol.

105. The composition according to claim 88, wherein the composition further comprises at least one pharmaceutically acceptable additive, lubricant, diluent, buffer, moistening agent, preservative agent, flavoring, adjuvant, carrier, stabilizer, suspending agent, emulsifying agent, propellant, or other vehicle.

106. A method for determining whether a substance increases or decreases the activity of at least one functional form of ATF6 in a cell whose production by a cell evokes a responsive change in at least one characteristic, comprising:

- providing a first cell line which produces at least one functional form of ATF6;

- providing a second cell line which produces the at least one functional form of ATF6 at a lower level than the first cell line, or does not produce the at least one functional form of ATF6 at all;

- contacting the substance with the first and second cell lines;

and

- comparing the at least one characteristic of the first cell lines with the second cell lines.

107. The method according to claim 106, whereby the at least one functional form of ATF6 is chosen from an endogenous form of ATF6, a full-length form of ATF6, an N-terminal domain form of ATF6, a bZIP-ATF6 fragment, functional derivatives thereof, and combinations thereof.

108. The method according to claim 106, whereby the first and second cell lines are neurons.

109. The method according to claim 106, whereby first and second cell lines are nigral neurons.

110. The method according to claim 106, whereby the at least one characteristic is chosen from a characteristic that is observable with the naked eye, a characteristic that is a cultural characteristic of the cell, a characteristic that is a morphological characteristic, and combinations thereof.

111. The method according to claim 106, whereby the at least one characteristic is a measure of an amount of ATF6 mRNA.

112. The method according to claim 106, whereby the at least one characteristic is a measure of an amount of at least one functional form of ATF6.

113. The method according to claim 106, whereby the at least one characteristic is chosen from a rate of cell death, a rate of cell proliferation, and combinations thereof.

114. The method according to claim 106, whereby the at least one characteristic is a response along the UPR signaling pathway.

115. The method according to claim 106, whereby the at least one characteristic is an expression of a gene chosen from Ire1, presenilin 1, presenilin 2, ATF6 regulated genes, and combination thereof.

116. The method according to claim 106, whereby the at least one characteristic is an expression of a UDR-regulated gene.

117. The method according to claim 116, whereby the UDR-regulated gene is chosen from a molecular chaperone BiP gene, a gene involved in protein glycosylation, a gene involved in protein secretion, a gene involved in protein degradation, a gene involved in membrane biosynthesis, and combinations thereof.

118. The method according to claim 106, whereby the at least one characteristic is a cleavage rate of a full length ATF6.

119. The method according to claim 106, whereby the at least one characteristic is a rate of protein folding.

120. The method according to claim 106, whereby the at least one characteristic is a measure of an amount of protein accumulation.

121. The method according to claim 106, whereby the at least one characteristic is chosen from a measure of an amount of protein aggregation, a measure of an amount of protein precipitation, a measure of an amount of protein plaques, and combinations thereof.

## FIGURES

Figure 1. Amino acid sequence of human ATF6- $\alpha$ ; SEQ ID NO: 4.

|            |             |             |            |            |            |
|------------|-------------|-------------|------------|------------|------------|
| 10         | 20          | 30          | 40         | 50         | 60         |
| MGEPAGVAGT | MESPFSPGLF  | HRLEDEDWDSA | LFAELGYFTD | TDELQLEAAN | ETYENNFDNL |
| 70         | 80          | 90          | 100        | 110        | 120        |
| DFDLDLLPWE | SDIWDINNQI  | CTVKDIKAEP  | QPLSPASSSY | SVSSPRSVDS | YSSTQHVPEE |
| 130        | 140         | 150         | 160        | 170        | 180        |
| LDLSSSSQMS | PLSLYGENSEN | SLSSPEPLKE  | DKPVTGSRNK | TENGLTPKKK | IQVNSKPSIQ |
| 190        | 200         | 210         | 220        | 230        | 240        |
| PKPLLLPAAP | KTQTNSSVPA  | KTIIIQTVPT  | LMPLAKQQPI | ISLQPAPTKG | QTVLLSQPTV |
| 250        | 260         | 270         | 280        | 290        | 300        |
| VQLQAPGVLP | SAQPVLAVAG  | GVTQLPNHVV  | NVVPAPSANS | PVNGKLSVTK | PVLQSTMRNV |
| 310        | 320         | 330         | 340        | 350        | 360        |
| GSDIAVLRRL | QRMKNRESA   | CQSRKKKKEY  | MLGLEARLKA | ALSENEQLKK | ENGLTKRQLD |
| 370        | 380         | 390         | 400        | 410        | 420        |
| EVVSENQRLK | VPSPKRRVVC  | VMIVLAFIIL  | NYGPMSMLEQ | DSRRMNPSVG | PANQRRHLLG |
| 430        | 440         | 450         | 460        | 470        | 480        |
| FSAKEAQDTS | DGIIQKNSYR  | YDHSVSNDKA  | LMVLTEEPLL | YIPPPPCQPL | INTTESLRNL |
| 490        | 500         | 510         | 520        | 530        | 540        |
| HELRGWVHRH | EVERTKSRRM  | TNNQOKTRIL  | QGVVEQGSNS | QLMAVQYTET | TSSISRNSGS |
| 550        | 560         | 570         | 580        | 590        | 600        |
| ELQVYYASPR | SYQDFFFAIR  | RRGDTFYVVS  | FRRDHLLLP  | TTHNKTTTPK | MSIVLPAINI |
| 610        | 620         | 630         | 640        | 650        | 660        |
| NENVINGQDY | EVMMQIDCQV  | MDTRILHIKS  | SSVPPYLRDQ | QRNQNTTFFG | SPPAATEATH |
| 670        |             |             |            |            |            |
| VVSTIPESLQ |             |             |            |            |            |

**Figure 1** (cont.)

Human ATF6- $\alpha$  has a length of 670 amino acids, with a molecular weight of 74,566 Da. Residues 1-150 are involved in transcription activation. Residues 308-328 comprise the basic domain that binds to DNA. Residues 334-369 comprise the leucine zipper. Residues 419-420 comprise the site cleaved by S1P. Residues 378-398 are involved in cleavage by S2P.

**Figure 2. Amino acid sequence of human ATF6- $\beta$ ; SEQ ID NO: 5.**

|            |             |            |            |            |             |
|------------|-------------|------------|------------|------------|-------------|
| 10         | 20          | 30         | 40         | 50         | 60          |
| MAELMLLSEI | ADPTRFFTDN  | LLSPEDWGLQ | NSTLYSGLDE | VAEEQTQLFR | CPEQDVFPDG  |
| 70         | 80          | 90         | 100        | 110        | 120         |
| SSLDVGMDVS | PSEPPWELLP  | IFPDLQVKSE | PSSPCSSSSL | SSESSLSTE  | PSSEALGVGE  |
| 130        | 140         | 150        | 160        | 170        | 180         |
| VLHVKTESLA | PPLCLLGDDP  | TSSFETVQIN | VIPTSDDSSD | VQTKIEPVSP | CSSVNSEASL  |
| 190        | 200         | 210        | 220        | 230        | 240         |
| LSADSSSQAF | IGEEVLEVKT  | ESLSPSGCLL | WDVPAPSLGA | VQISMGPSLD | GSSGKALPTR  |
| 250        | 260         | 270        | 280        | 290        | 300         |
| KPPLQPKPVV | LTTVPMPSTRA | VPPSTTVLLQ | SLVQPPPVSP | VVLIQGAIRV | QPEGAPAPSLP |
| 310        | 320         | 330        | 340        | 350        | 360         |
| RPERKSIVPA | PMPGNSCPPE  | VDKLLKRQQ  | RMKNRESAC  | QSRKKKEYL  | QGLEARLQAV  |
| 370        | 380         | 390        | 400        | 410        | 420         |
| LADNQQLRRE | NAALRRRLEA  | LLAENSELKL | GSGNRKVVCV | MVLLFIAPN  | FGPVSISEPP  |
| 430        | 440         | 450        | 460        | 470        | 480         |
| SAPISPRMNK | GEPQPRRHL   | GFSEQEPVQG | VEPLQGSSQG | PKEPQPSPTD | QPSFSNLTA   |
| 490        | 500         | 510        | 520        | 530        | 540         |
| PGGAKELLRL | DLDQLFLSSD  | CRHFNRTESL | RLADELSGWV | QRHQRGRRKI | PQRAQERQKS  |
| 550        | 560         | 570        | 580        | 590        | 600         |
| QPRKKSPPVK | AVPIQPPGPP  | ERDSVGQLQL | YRHPDRSQPA | FLDAIDRRD  | TFYVVSFRD   |
| 610        | 620         | 630        | 640        | 650        | 660         |
| HLLLPAISHN | KTSRPKMSLV  | MPAMAPNETL | SGRGAPGDYE | EMMQIECEVM | DTRVIHIKTS  |
| 670        | 680         | 690        | 700        |            |             |
| TVPPSLRKQP | SPTPGNATGG  | PLPVSAASQA | HQASHQPLYL | NHP        |             |

**Figure 2 (cont.)**

Human ATF6- $\beta$  has a length of 703 amino acids, with a molecular weight of 76,709 Da. Residues 1-86 are involved in transcription activation. Residues 327-347 comprise the basic domain that binds to DNA. Residues 367-388 comprise the leucine zipper. Residues 440-441 comprise the site cleaved by S1P. Residues 410 and 413, independently, are important for cleavage by S2P.

**Figure 3. Amino acid sequence of murine ATF6- $\alpha$  (Fragment); SEQ ID NO: 6.**

|            |            |            |             |             |            |
|------------|------------|------------|-------------|-------------|------------|
| 10         | 20         | 30         | 40          | 50          | 60         |
| LTHPSCEGEV | SVSGKPACVA | GAMESPFSPV | LPHGPDDEWE  | STLFAELGYF  | TDTDDVHFDA |
| 70         | 80         | 90         | 100         | 110         | 120        |
| AHEAYENNF  | HLNFDLDLMP | WESDLWSPGS | HFCSDMKAEP  | QPLSPASSSC  | SISSPRSTDS |
| 130        | 140        | 150        | 160         | 170         | 180        |
| CSSTQHVPEE | LDLLSSSQSP | LSLYGDSCNS | PSSVEPLKEE  | KPVTGPGNKT  | EHGLTPKKKI |
| 190        | 200        | 210        | 220         | 230         | 240        |
| QMSSKPSVQP | KPLLLPAAPK | TQTNASVPAK | AIIIQTLPAL  | MPLAKQQSII  | SIQPAPTKGQ |
| 250        | 260        | 270        | 280         | 290         | 300        |
| TVLLSQPTVV | QLQSPAVLSS | AQPVLAVTGG | AAQLPNHVVN  | VLPAPVVSSP  | VNGKLSVTKP |
| 310        | 320        | 330        | 340         | 350         | 360        |
| VLQSATRSMG | SDIAVLRQQ  | RMIKNRESAC | QSRKKKKKEYM | LGLEARLKA   | LSENEQLKKE |
| 370        | 380        | 390        | 400         | 410         | 420        |
| NGSLKRQLDE | VVSENQRLKV | PSPKRRAVCV | MIVLAFIMLN  | YGPMMSLEQE  | SRRVKPSVSP |
| 430        | 440        | 450        | 460         | 470         | 480        |
| ANQRRHLLF  | SAKEVKDTS  | GDNQKDSYS  | DHSVSNDKAL  | MVPSEEPLLY  | MPPPPCQPLI |
| 490        | 500        | 510        | 520         | 530         | 540        |
| NTTESLRLNH | ELRGWVHRHE | VERTKSRRMT | NSQQKARILQ  | GALEQGSNSQ  | LMAVQYTETT |
| 550        | 560        | 570        | 580         | 590         | 600        |
| SISRNSGSEL | QVYYASPGSY | QGFFDAIRRR | GDTFYVVSFR  | RDHLLLPATT  | HNKTTRPKMS |
| 610        | 620        | 630        | 640         | 650         | 660        |
| IVLPAININD | NVINGQDYEV | MMQIDCQVMD | TRILHIKSSS  | VPPYL RDHQR | NQTSTFFGSP |
| 670        |            |            |             |             |            |
| PTTTETTHVV | STIPESLQ   |            |             |             |            |

**Figure 4. Amino acid sequence of murine ATF6- $\beta$ ; SEQ ID NO: 7.**

|            |             |            |            |            |            |
|------------|-------------|------------|------------|------------|------------|
| 10         | 20          | 30         | 40         | 50         | 60         |
| MAELMLLSEI | ADPTRFFTDN  | LLSPEDWDST | LYSGLDEVAE | EQAQLFRCVE | QDVFPDSSSL |
| 70         | 80          | 90         | 100        | 110        | 120        |
| DVGMDVSPPE | PPWDPLPIFP  | DLQVKSEPSS | PCSSSSLSSE | SSHLSTEPS  | QVPGVGEVLH |
| 130        | 140         | 150        | 160        | 170        | 180        |
| VKMESLAPPL | CLLGDDPASP  | FETVQITVGS | ASDDLSDIQT | KLEPASPS   | VHSEASLLSA |
| 190        | 200         | 210        | 220        | 230        | 240        |
| DSPSQPFIGE | EVLEVKTESP  | SPPGCLLWDV | PASSLGAVQI | SMGPSPDSSS | GKAPATRKPP |
| 250        | 260         | 270        | 280        | 290        | 300        |
| LQPKPVVLT  | VPVPPRAGPT  | SAAVLLQPLV | QQPAVSPVVL | IQGAIRVQPE | GPAPAAPRPE |
| 310        | 320         | 330        | 340        | 350        | 360        |
| RKSIVPAPMP | GNSCPPEVDA  | KLLKRQQMI  | KNRESACQSR | RKKKEYLQGL | EARLQAVLAD |
| 370        | 380         | 390        | 400        | 410        | 420        |
| NQQLRRENA  | LRRRLLEALLA | ENSGCLKGSG | NRKVVCIMVF | LLFIAFNFGP | VSISEPPPAP |
| 430        | 440         | 450        | 460        | 470        | 480        |
| MSPRMSREEP | RPQRHLLGFS  | EPGPAHGMEP | LREAAQSPGE | QQPSSAGRPS | FRNLTAFPGG |
| 490        | 500         | 510        | 520        | 530        | 540        |
| AKELLLRLD  | QLFLSSDCRH  | FNRTESLRLA | DELSGWVQRH | QRGRRKIPHR | AQERQKSQLR |
| 550        | 560         | 570        | 580        | 590        | 600        |
| KKSPVVKPVP | TQPPGPPERD  | PVGQLQLYRH | PGRSQPEFLD | AIDRRDFTFY | VVSFRRDHLL |
| 610        | 620         | 630        | 640        | 650        | 660        |
| LPAISHNKTS | RPKMSLVMPA  | MAPNETVSGR | GPPGDYEEMM | QIECEVMDTR | VIHIKTSTVP |
| 670        | 680         | 690        |            |            |            |
| PSLRKQSPSP | PGNTTGGPLP  | GSAASPAHQA | SQPLYLNHP  |            |            |

**Figure 4** (cont.)

Murine ATF6- $\beta$  has a length of 699 amino acids, with a molecular weight of 76,007 Da. Residues 324-344 represent the basic domain that binds to DNA. Residues 364-385 represent the leucine zipper. Residues 437-438 represent the cleavage site by S1P. Residues 407 and 410, independently, are important for cleavage by S2P.

**Figure 5. DNA sequence of human ATF6- $\alpha$ ; SEQ ID NO: 8.**

```

1  aagatattaa  tcacggagtt  ccagggaaaa  ggaacttgtg  aaatggggga  gccggctggg
61  gttgccggca  ccatggagtc  accttttagc  ccgggactct  ttcacaggct  ggatgaagat
121  tgggattctg  ctctctttgc  tgaacttggg  tatttcacag  acactgatga  gctgcaattg
181  gaagcagcaa  atgagacgta  tgaaaacaat  tttgataatc  ttgattttga  tttggatttg
241  ttaccttggg  agtcagacat  ttgggacatc  aacaaccaaa  tctgtacagt  taaagatatt
301  aaggcagaac  cccagccact  ttctccagcc  tcctcaagtt  attcagtcct  atctcctcgg
361  tcagtggact  cttattcttc  aactcagcat  gttcctgagg  agttggattt  gtcttctagt
421  tctcagatgt  ctcccccttc  cttatatggt  gaaaactcta  atagtctctc  ttcaccggag
481  ccactgaagg  aagataagcc  tgtcactggg  tctaggaaca  agactgaaaa  tggactgact
541  ccaaagaaaa  aaattcagg  gaattcaaaa  ccttcaattc  agcccaagcc  tttatttgctt
601  ccagcagcac  ccaagactca  aacaaactcc  agtggtccag  caaaaacccat  cattattcag
661  acagtaccaa  cgcttatgcc  attggc aaag  cagcaaccaa  ttatcagttt  acaacctgca
721  cccactaaaag  gccagacggg  tttgctgtct  cagcctactg  tgggtacaact  tcaagcacct
781  ggagtctctg  cctctgtctc  gccagtcctt  gctgttgctg  ggggagtcac  acagctccct
841  aatcacgtgg  tgaatgtggg  accagccctt  tcagcgaata  gccagtgaa  tggaaaactt
901  tccgtgacta  aacctgtcct  acaaagtacc  atgagaaatg  tcggttcaga  tattgtgtg
961  ctaaggagac  agcaacgtat  gataaaaaat  cgagaatccg  cttgtcagtc  tcgacaagaag
1021  aagaaagaat  atatgctagg  gttagaggcg  agattaaagg  ctgccctctc  agaaaacgag
1081  caactgaaga  aagaaaatgg  aacactgaag  cggcagctgg  atgaagttgt  gtcagagaac
1141  cagaggctta  aagtccctag  tccaaagcga  agagtgtct  gtgtgatgat  agtattggca
1201  tttataatac  tgaactatgg  acctatgagc  atgttgaac  aggtatccag  gagaatgaac
1261  cctagtgtgg  gacctgcaaa  tcaaaggagg  caccttctag  gattttctgc  taaagaggca
1321  caggacacat  cagatggtat  tatccagaaa  aacagctaca  gatatgatca  ttctgtttca
1381  aatgacaaaag  ccctgatggg  gctaactgaa  gaaccattgc  ttacattcc  cccacctcct
1441  tgtcagcccc  taattaatac  aacagagtct  ctcaggttaa  atcatgaact  tcgaggatgg
1501  gttcatagac  atgaagtaga  aaggaccaag  tctagaagaa  tgacaaataa  tcaacagaaa
1561  acccggtatt  ttcagggtgt  tgtggaacag  ggctcaaatt  ctcagctgat  ggctgttcaa
1621  tacacagaaa  ccactagtag  tatcagcagg  aactcagggg  gtgagctaca  agtgatttat
1681  gcttcaccca  gaagttatca  agactttttt  gaagccatcc  gcagaagggg  agacacattt
1741  tatgttgtgt  cttttcgaag  ggatcacctg  ctgttaccag  ctaccacca  taacaagacc
1801  acaagaccaa  aaatgtcaat  tgtgttacca  gcaataaaca  taaatgagaa  tgtgatcaat
1861  gggcaggact  acgaagtgat  gatgcagatt  gactgtcagg  tgatggacac  caggatcctc
1921  catatcaaaa  gttcgtcggt  tcctccttac  ctccgagatc  agcagaggaa  tcaaaccaac
1981  acctctcttg  gctccccctc  cgcagccaca  gaggcaacc  acgttgtcag  caccatccct
2041  gagtcattac  aatagcacc  gcagctatgt  ggaaaactga  gcgtgggacc  cccagactga
2101  agagcagggt  agcaaaatgc  tgcttttctt  tggtggcagg  cagagaactg  ttcgtactag
2161  aattcaagga  gaaaagaaga  agaaaataaaa  gaagctgctc  catttttcat  catctacca
2221  tctatttggg  aagcactgga  attcagatgc  aagagaacaa  tgtttcttca  gtggcaaatg
2281  tagccctgca  tcctccagt  ttacctgggt  tagatttttt  tttctgtacc  tttctaaacc
2341  tctcttccct  ctgtgatggg  tttgtgttta  aacagtcac  ttcttttaaa  taatatccac
2401  ctctcctttt  tgccatttca  cttattgatt  cataaagtga  attttattta  aagctaaaaa
2461  aaaaaaaaaa  aaaa

```

**Figure 6. DNA sequence of human ATF6- $\beta$ ; SEQ ID NO: 9.**

```

1  aaccgtctcc  tggttggggg  gtggggggga  aagatggcgg  agctgatgct  gctcagcgag
61  attgctgacc  cgacgcgttt  cttcaccgac  aacctgctta  gcccggagga  ctgggggtctg
121  cagaacagca  ccttgatttc  tggcctagat  gaagtggccg  aggagcagac  gcagctcttc
181  cgttgcccg  agcaggatgt  cccgtttgac  ggcagctccc  tggacgtggg  gatggatgtc
241  agccccctctg  agcccccatg  ggaactcctg  ccgatcttcc  cagatcttca  ggtgaagtct
301  gagccatctt  cccccctgctc  ttctctctcc  ctcagctccg  agtcacgcgg  tctctccaca
361  gagccatcca  gcgaggtctc  tggggtaggg  gaggtgctcc  atgtgaagac  agagtccctg
421  gcacccccac  tgtgtctcct  gggagatgac  ccaacatcct  catttgaaac  cgtccagatc
481  aatgttatcc  ccacctctga  tgattctca  gatgtccaga  ccaagataga  acctgtctct
541  ccattgttctt  ccgtcaactc  tgaggcctcc  ctgctctcag  ccgactcttc  cagccaggct
601  tttataggag  aggaggtcct  ggaagtgaag  acagagtccc  tgtccccctc  aggatgcctc
661  ctgtgggatg  tcccagcccc  ctcacttgga  gctgtccaga  tcagcatggg  cccatccctt
721  gatggctcct  caggcaaagc  cctgcccacc  cggaagccgc  cactgcagcc  caaacctgta
781  gtgtctaacca  ctgtcccaat  gccatccaga  gctgtgcctc  ccagaccac  agtcttctg
841  cagtccctcg  tccagccacc  cccagtgtcc  ccagtgtgct  tcatccaggg  tgctattcga
901  gtccagcctg  aagggccggc  tccctctcta  ccacggcctg  agaggaagag  catcgttccc
961  gctcctatgc  ctggaaactc  ctgcccgcct  gaagtggatg  caaagctgct  gaagcggcag
1021  cagcgaatga  tcaagaaccg  ggagtcagcc  tgccagtccc  ggagaaagaa  gaaagagtat
1081  ctgcagggac  tggaggtcct  gctgcaagca  gtactggctg  acaaccagca  gctccgcca
1141  gagaatgctg  cctccggcg  gcggctggag  gccctgctgg  ctgaaaacag  cgagctcaag
1201  ttagggtctg  gaaacaggaa  ggtggtctgc  atcatggtct  tcttctctct  cattgccttc
1261  aactttggac  ctgtcagcat  cagtgcagct  ccttcagctc  ccatctctcc  tcggatgaac
1321  aagggggagc  ctcaaccccg  gagacacttg  ctgggggtct  cagagcaaga  gccagttcag
1381  ggagttgaac  ctctccagg  gtctcccag  ggccctaagg  agccccagcc  cagccccaca
1441  gaccagccca  gtttcagcaa  cctgacagcc  ttccctgggg  gcgccaagga  gctactacta
1501  agagacctag  accagctctt  cctctctct  gattgccggc  acttcaaccg  cactgagtcc
1561  ctgaggcttg  ctgacgagtt  gagtggctgg  gtccagcgcc  accagagagg  ccggagggaag
1621  atccctcaga  gggcccagga  gagacagaag  tctcagccac  ggaagaagtc  acctccagtt
1681  aaggcagtc  ccatccaacc  ccctggaccc  ccagaaagg  attctgtggg  ccagctgcaa
1741  ctatatcgcc  acccagaccg  ttccgagcca  gcattcttgg  atgcaattga  ccgacgggaa
1801  gacacatttt  atgttgtctc  tttccgaagg  gaccacctgc  tgctcccagc  catcagccac
1861  aacaagacct  cccggcccaa  gatgtccctg  gtgatgcctg  ccatggcccc  caatgagacc
1921  ctgtcaggcc  gtggggcccc  gggggactat  gaggagatga  tgcagatcga  gtgtgaggtc
1981  atggacacca  gggtgattca  catcaagacc  tccacagtgc  cccctcgt  ccgaaaacag
2041  ccatcccaa  ccccaggcaa  tgccacaggt  ggccccttgc  cagtctctgc  agccagccag
2101  gcccaccagg  cctcccacca  gcccctctac  ctcaatcatc  cctgacctct  gccattcaca
2161  ctgacttaga  acggggggag  ggggtaccag  gtggccaggt  gggactgttt  caaatttccc
2221  tgatccccag  gcttggggca  attggtaaag  gaaagagcag  gtgtgggggt  taagcactta
2281  tttgaggtgg  ggggtgttcac  ctctcttctc  atcccttttc  agaatatagg  gtcctctca
2341  ttctgtgaa  ccccagtc  tggcttcttt  gtttgagggg  attgtgtgag  gttcagttgt
2401  ggggtgggtg  gtgagctgct  gcataatttt  tattttgttt  ctctagtgtt  atggcagtg
2461  aggtgggaat  ttagtcccca  ggtgggacaa  gggaggtttt  ttcattttgg  agctagttac
2521  tgggagtaag  ggaggggtgg  gtggggggga  gttcaggttt  atgtgtgtgc  atttctttt
2581  tattattatt  aaataaacia  cttggaggga  gttgaaaaaa  aa

```

**Figure 7. DNA sequence of murine ATF6- $\alpha$ ; SEQ ID NO: 10.**

```

1  ccggagggag aggtgtctgt ttcggggaag ccggttctgt ttgccggcgc catggagtcg
61  ccttttagtc cggttcttcc tcatggacca gatgaagact gggagtcgac gttgtttgct
121  gaacttggtt atttcacaga cactgatgat gtgcactttg atgcagcaca tgaggcttat
181  gaaaataatt ttgatcatct taattttgat ttggatttga tgccttggga gtcagacctt
241  tggagccccg gcagccactt ctgctcagac atgaaggcag agccccagcc tctttctccg
301  gcttcctcca gttgctccat ctctctcctt cgggtccacag actcgtgttc ttcaactcag
361  cacgttctctg aggagttgga tttgttgtct agttctcagt ccccccttcc cttatatggc
421  gacagctgta atagcccctc ctctgtagag ccactgaagg aagagaagcc tgtcactggg
481  cctggaaaca aaacagaaca tggactgact ccaaagaaaa aaattcagat gagtttaaaa
541  ccttcagttc agcccaagcc tttattactt ccagcagcgc ccaagactca aaccaatgcc
601  ggtgtcccag caaaagccat catcattcag acactaccag cccttatgcc actggcaaaag
661  cagcagtcga ttatcagcat acagcctgcg cccaccaaag gccagactgt tttgctctct
721  cagccgactg tggttcaact tcagagccct gcggttctgt cgtctgctca gccggttctt
781  gcagtcactg ggggagccgc acagctacct aacctgtggg tgaattgttg ctggccagcc
841  ccctgtggtg agcagcccg tgaatggaaa actttccgtg actaaacctg ttctacaaag
901  tgccaccaga agtatgggtt cggatatcgc tgtgctgagg agacagcagc ggatgataaa
961  gaaccgagag tctgcttgtc agtcgcgcaa gaagaagaaa gagtatatgc taggactgga
1021  ggccaggcct caaggctgcc ctctcataga atgagcagct gtagaaggag aatggctccc
1081  tgaagcgaca gctggacgag gtggtgtcag agaaccagag gctcaaagtc ccaagtccaa
1141  agcgaagagc tgtctgtgtg atgatagtat tagcatttat aatgctgaac tatgggcccc
1201  tgagcatgct ggagcaagaa tcccgaagag tgaaacctag tgtgagccct gccaatcaga
1261  ggaggcatct cttggaattt tcagcaaaag aagttaaaga cacatcagat ggtgacaacc
1321  agaaaagacag ttacagctat gatcactctg tgtccaatga caaagcttta atggtgctaa
1381  gtgaagagcc attgctttat atgcctccac ctccatgtca accctgattt aacacaacag
1441  agtctctcag gttgaacctt gaacttcgag gctgggttca tagacatgaa gtggaaagga
1501  ccaaacttag aagaatgaca aatagccaac agaaagcccg cattctccag ggtgctctgg
1561  aacagggctc taattctcag ctgatggctg tccagtacac agaaaccact agcatcagta
1621  ggaattctgg gagtgagctg caagtgtatt acgcctcccc tggaagttac caaggcttct
1681  ttgacgccat ccgcaggagg ggagatacgt tttacgttgt ctcatctcga agggatcatc
1741  tgctattacc agctaccacc cacaacaaga ccacaagacc aaaaatgtca attgtattac
1801  cagcaataaa cataaatgat aatgtgatca atgggcagga ctatgaagta atgatgcaga
1861  ttgactgtca ggtgatggac accaggatcc tccacatcaa aagctcctcg gttccccctt
1921  atctccggga tcatcagcgg aaccaaaacca gcacctctt tggttccccct ccaacaacca
1981  cagagacgac ccatgtggtc agcaccatcc ctgagtcgtt gcagtagtgc ccgagctgcg
2041  ctggacagca gagactgaag agctggtgaa gatgctgctc tctgctctt cggcaagcag
2101  agacttgctt tgtacgcaac tccaggggaa gaggaagaga gaacagggaag tgcgctgctt
2161  gtcaccgtcc acccagtggg gtggaacatg ctacgagcag attctctggt ggcagtgcag
2221  ccctgtgggc agtgtcgcct ggtgttggtt ctgctgtgtc atcttttagtg cttttctcaa
2281  tgtgtgtttg gttctcagtt atcttctctc aggtcagacc cacttctctt tctgtccact
2341  gcacttctctg gtgcagtaaa gagatttgta tttaaagctt tagaacacat gctcatgtgg
2401  tttccaccaa ttggctttct ctctcctttg gttcaaattc attctgaatg ttatacttga
2461  gaaaacacat ttcaaaaaac cgagcagcca aaaacatccc acaagagtc aaaacagttt
2521  agagtttggg taaagggatt atctccagtt ggtaagagtt tatttttact tgtgatttgt
2581  ggttcagccc tggacaaata actgttgttg ggttcacaga gtgagccaca cactggagac
2641  aaggggaagg aaggccagtg gtggaatgta aggggaagtg actccatttt catatgtatt
2701  taaacacaga gttcctgtgg cctcggtgaa ctacagagcta tagccacctt cagtgttgga
2761  actcggctaa tcagcagaga tcttcaaaga tctcagggca catgcttgcc tctcattgtg
2821  gaccctcagc ccagagcata ctctgtgaa accagactca gcaaagggac ttggaggtca
2881  ctaggcttaa gcaagactag agagtttccc ttaaggacca acagtgcaca gagcaagcat
2941  ggcttcccag agaagctgca gcacagtatg gtgaagttct cagtttttcc agtggaaaga
3001  tgataaagga attaaagctt cttgtgtgtt gctatggctg tgaacatggc tttaatccta
3061  gcaccatttg gaaggaaagg caggctttgt ttgatatcag cctggcctac atttcaaatt
3121  ccaggacagg acagctaaag ctatataaag aacccacctc aaaaaataga tgaatgaata
3181  aatgagtaaa taaacaaata caaacaacaa gcaaagttaa gttcacatat attttattgt
3241  attttgcttg cttccttcac catagcaagc agccacattt ctattgcaat gtacattgta
3301  cgttacaagt tcacagaaat ggatgccagg actcatgtca gtcagtgtgt gcctcccttc
3361  ccaggatttc agcaggttct catagactct tcccagcctg gcttgcccat tgtcagggtg

```

**Figure 7. (cont.)**

```
3421 tcccattcca gtaagcaciaa tggcggttaa gtcctcttct ctctacaagg agtgacacac
3481 agtcaggtea tcttttgctt gtggcccat tatgcctggc actgttcacc aacaactgtt
3541 ccttgacag cactgctgcc atctaagcta aggtgagatg ttttcggggc agggccattc
3601 ttgctgaatt cagtgccgca gtccatcctg attggctctc ggggtgatttt cagacaagac
3661 ctgtttgtcc cgggggctgg tcctctaata ggtgccaagg agaagatacc aaatacatgg
3721 agtaccttta ggagtagcca tttgtggggg aggttgggct accctgtggc catgttcttc
3781 ctgcctgtga agcagctcaa aacgaggatg tgactgtggg ctgtggacag aggcagcaca
3841 cgcattcctg atgctgatct gctgagacac gaatagaatc tgcagtgact ccagtgtacc
3901 agtgctcag atcaaagacc tcaatagtgt cacgtttgct aaggctgatg cctctcctac
3961 aggtaacagt ggggatgacc gttggaaggc acagccaaag agcagacaga agttaagggtg
4021 gccacagcac aggtcaggga tccaaggagc tggggaggac tgctcaaaac tagtctggaa
4081 gcttgcttcc tctgctcctg ctgaccatca ggtcctgtca ttaccactct cagggtccgtc
4141 ttatgagatg aggaatgggg cctctctcag gggagagttt cagaaatgag ggaaaggcaa
4201 ttatagatag aaagaagtat cctgccattt aaattgctga aagagctaga atccctgggc
4261 tcggtagttt gtatcttaat gtttgtgcgc tagcacaggc ccattggaga ggaaaagctg
4321 ttgtcctggg agcaaagtaa gcagccattc aggtctcatt ttttattttg gtatgcttgc
4381 ccttgggtgt ttatagcccg gaactgtagg agctatgtat gtacataata tatatatttt
4441 ttaattt
```

**Figure 8. DNA sequence of murine ATF6- $\beta$ ; SEQ ID NO: 11.**

```

1  gcggggagcc gggtcatggt ggggggtggg gggaagatgg cggagctgat gctcctcact
61  gagatcgccg acccgacgcg cttcttcacc gacaacctgc tgagtccgga ggactgggac
121 agcaccttgt acagtggcct ggatgaagtg gccgaggagc aggcacagtt gttccgttgc
181 gtggagcagg atgtcccgtt tgacagcagc tctctggatg tggggatgga tgtcagcccc
241 cctgagcccc cttgggaccc tctacccatc ttcccagatc ttcaggtgaa gtccgagcca
301 tctctccctt gctcgtcctc ctccctcagc tcagagtccct cacatctttc cacagagccc
361 cccagccagg tccctggtgt aggcgaggtg ctgcatgtga agatggagtc cctggcacc
421 cactctgcc tgcctgggga tgatccagca tccccctttg aaacgggtcca gatcactgtg
481 ggctctgcct ctgatgatct ttcagatata cagaccaagc tggaaacctgc ctctccgtct
541 tcttctgtcc actctgaggg ctccttgcct tcagcagact ctcccagtcg gccttttata
601 ggagaggagg ttctggaagt gaagacagag tctccgtccc ctccagggtg ctcctgtgg
661 gatgtccccc cctcttcgct cggagctgtc cagatcagca tgggtccatc cctctgatgt
721 tcctcaggga aagctccggc cactcgggaag cctccactgc agcccaagcc tgtggtacta
781 accacagttc cgggtgccacc tagagctggg cctaccagcg ctgcccgtcc cctgcaaccc
841 ctggtccagc agcctgcggg gtccccagtg gtcccatcc aaggtgctat ccgagtcag
901 cctgaagggc cagctcccgc agctcccggg cctgagagga agagcattgt tccagcccc
961 atgcccggga actcctgccc gcctgaagtg gatgcaaagc tgttgaagcg gcagcagcg
1021 atgatcaaga atcgagagtc ggctgcccag tcccgcgcga agaagaaaga gtacctgcca
1081 aggcctggag gccccggctg caggctgtgc tggccgacaa ccagcagctg cgcagggaga
1141 acgctgccct ccggcggcgg ctggaggccc tgcctggcaga gaacagcggg ctcaagctgg
1201 ggtctgggaa caggaagggt gtctgcatca tggctctcct tctcttcatt gccttcaact
1261 tttggcctgt gagcatcagc gagccgcctc cagctcccat gtctcctcgg atgagcagg
1321 aggaacctcg accccagagg cacctgctgg gcttctcaga accagggccg gctcatggca
1381 tggaaacctt tcgggaagcc gccagagacc ccggggagca gcagcccagc tctgcaggca
1441 ggcccagctt cagaaacctg acggccttcc ccgggggagc caaggaggct gctgctgaga
1501 gacctggacc agctcttctc ctccctcagc tgcgccatt tcaaccgaac tgagtctctg
1561 aggcttgctg atgagctgag tggctgggtc caacgtcacc agagaggtcg acggaagata
1621 cctcacaggg ccaggagag acagaagtct cagctacgga agaagtctcc tccagtga
1681 cctgtcccca cccaacctcc aggacccctt gaaagggaac ccgtgggcca gctgcagctc
1741 taccgccacc ccggccgctc gcagccggag tttctagacg caattgaccg gagggaggat
1801 accttctatg ttgtctcctt ccgaagggac cacctgctgc tcccagccat cagccaccac
1861 aagacatcca ggccccagat gtcgtggtg atgccagcca tggcccccaa tgagaccgtg
1921 tcaggccggg gccccccagg ggactatgag gagatgatgc agatcgagtg tgaggtcatg
1981 gacaccaggg tgattcacat caagacctct acggtgcccc cctcgtcccg gaagcagccg
2041 tccccatccc cgggcaatac cacaggtggc cccttgccag gctccgcagc tagtctgcc
2101 catcaggcct ccagccccct ttacctcaat caccctgac atcctcacct cacagtgact
2161 tagaaccggg ttagggaaac tgatcctggg gctcgggggc aattgtaaag gaagacgggg
2221 tgtgggggtt aagcacttag tgggactagg gtgggtggtt cactctctt ctcactctt
2281 ccagaaatat agggctcctc tcattcctgc actcccagtc ctctttcccc gagggtaact
2341 cgtgagggtt tccccatat cctcttcatt ctctccttta tctgtttggg agtcaagggtg
2401 ggactagggt gccagggtgg acaagggtg gtgtgggtg gcagaagtca gtttatgtgt
2461 gtgcgtatct tttttttatt attattaaat aaacaacgtg gaggggtgta aagg

```

## SEQUENCE LISTING

<110> Elan Pharmaceuticals, Inc.  
Zhao, Byron  
Mei, Yu

<120> Neuroprotective Effects of ATF6

<130> 08576.0004-00304

<140> PCT claims priority to US 60/491,565

<141> 2004-07-30

<150> 60/491,565

<151> 2003-08-01

<160> 11

<170> PatentIn version 3.2

<210> 1

<211> 10

<212> DNA

<213> human, rat, murine

<400> 1

ggtgacgtgg

10

<210> 2

<211> 10

<212> DNA

<213> human, rat, murine

<400> 2

ggtgacgtga

10

<210> 3

<211> 19

<212> DNA

<213> human, rat, murine

<400> 3

ccaatcggcg gcggccacg

19

<210> 4

<211> 670

<212> PRT

<213> human

<400> 4

Met Gly Glu Pro Ala Gly Val Ala Gly Thr Met Glu Ser Pro Phe Ser  
1 5 10 15

Pro Gly Leu Phe His Arg Leu Asp Glu Asp Trp Asp Ser Ala Leu Phe  
20 25 30

Ala Glu Leu Gly Tyr Phe Thr Asp Thr Asp Glu Leu Gln Leu Glu Ala  
35 40 45

Ala Asn Glu Thr Tyr Glu Asn Asn Phe Asp Asn Leu Asp Phe Asp Leu  
50 55 60

Asp Leu Leu Pro Trp Glu Ser Asp Ile Trp Asp Ile Asn Asn Gln Ile  
 65 70 75 80  
 Cys Thr Val Lys Asp Ile Lys Ala Glu Pro Gln Pro Leu Ser Pro Ala  
 85 90 95  
 Ser Ser Ser Tyr Ser Val Ser Ser Pro Arg Ser Val Asp Ser Tyr Ser  
 100 105 110  
 Ser Thr Gln His Val Pro Glu Glu Leu Asp Leu Ser Ser Ser Ser Gln  
 115 120 125  
 Met Ser Pro Leu Ser Leu Tyr Gly Glu Asn Ser Asn Ser Leu Ser Ser  
 130 135 140  
 Pro Glu Pro Leu Lys Glu Asp Lys Pro Val Thr Gly Ser Arg Asn Lys  
 145 150 155 160  
 Thr Glu Asn Gly Leu Thr Pro Lys Lys Lys Ile Gln Val Asn Ser Lys  
 165 170 175  
 Pro Ser Ile Gln Pro Lys Pro Leu Leu Leu Pro Ala Ala Pro Lys Thr  
 180 185 190  
 Gln Thr Asn Ser Ser Val Pro Ala Lys Thr Ile Ile Ile Gln Thr Val  
 195 200 205  
 Pro Thr Leu Met Pro Leu Ala Lys Gln Gln Pro Ile Ile Ser Leu Gln  
 210 215 220  
 Pro Ala Pro Thr Lys Gly Gln Thr Val Leu Leu Ser Gln Pro Thr Val  
 225 230 235 240  
 Val Gln Leu Gln Ala Pro Gly Val Leu Pro Ser Ala Gln Pro Val Leu  
 245 250 255  
 Ala Val Ala Gly Gly Val Thr Gln Leu Pro Asn His Val Val Asn Val  
 260 265 270  
 Val Pro Ala Pro Ser Ala Asn Ser Pro Val Asn Gly Lys Leu Ser Val  
 275 280 285  
 Thr Lys Pro Val Leu Gln Ser Thr Met Arg Asn Val Gly Ser Asp Ile  
 290 295 300  
 Ala Val Leu Arg Arg Gln Gln Arg Met Ile Lys Asn Arg Glu Ser Ala  
 305 310 315 320  
 Cys Gln Ser Arg Lys Lys Lys Lys Glu Tyr Met Leu Gly Leu Glu Ala  
 325 330 335

Arg Leu Lys Ala Ala Leu Ser Glu Asn Glu Gln Leu Lys Lys Glu Asn  
 340 345 350  
 Gly Thr Leu Lys Arg Gln Leu Asp Glu Val Val Ser Glu Asn Gln Arg  
 355 360 365  
 Leu Lys Val Pro Ser Pro Lys Arg Arg Val Val Cys Val Met Ile Val  
 370 375 380  
 Leu Ala Phe Ile Ile Leu Asn Tyr Gly Pro Met Ser Met Leu Glu Gln  
 385 390 395 400  
 Asp Ser Arg Arg Met Asn Pro Ser Val Gly Pro Ala Asn Gln Arg Arg  
 405 410 415  
 His Leu Leu Gly Phe Ser Ala Lys Glu Ala Gln Asp Thr Ser Asp Gly  
 420 425 430  
 Ile Ile Gln Lys Asn Ser Tyr Arg Tyr Asp His Ser Val Ser Asn Asp  
 435 440 445  
 Lys Ala Leu Met Val Leu Thr Glu Glu Pro Leu Leu Tyr Ile Pro Pro  
 450 455 460  
 Pro Pro Cys Gln Pro Leu Ile Asn Thr Thr Glu Ser Leu Arg Leu Asn  
 465 470 475 480  
 His Glu Leu Arg Gly Trp Val His Arg His Glu Val Glu Arg Thr Lys  
 485 490 495  
 Ser Arg Arg Met Thr Asn Asn Gln Gln Lys Thr Arg Ile Leu Gln Gly  
 500 505 510  
 Val Val Glu Gln Gly Ser Asn Ser Gln Leu Met Ala Val Gln Tyr Thr  
 515 520 525  
 Glu Thr Thr Ser Ser Ile Ser Arg Asn Ser Gly Ser Glu Leu Gln Val  
 530 535 540  
 Tyr Tyr Ala Ser Pro Arg Ser Tyr Gln Asp Phe Phe Glu Ala Ile Arg  
 545 550 555 560  
 Arg Arg Gly Asp Thr Phe Tyr Val Val Ser Phe Arg Arg Asp His Leu  
 565 570 575  
 Leu Leu Pro Ala Thr Thr His Asn Lys Thr Thr Arg Pro Lys Met Ser  
 580 585 590  
 Ile Val Leu Pro Ala Ile Asn Ile Asn Glu Asn Val Ile Asn Gly Gln  
 595 600 605

Asp Tyr Glu Val Met Met Gln Ile Asp Cys Gln Val Met Asp Thr Arg  
610 615 620

Ile Leu His Ile Lys Ser Ser Ser Val Pro Pro Tyr Leu Arg Asp Gln  
625 630 635 640

Gln Arg Asn Gln Thr Asn Thr Phe Phe Gly Ser Pro Pro Ala Ala Thr  
645 650 655

Glu Ala Thr His Val Val Ser Thr Ile Pro Glu Ser Leu Gln  
660 665 670

<210> 5  
<211> 703  
<212> PRT  
<213> human

<400> 5

Met Ala Glu Leu Met Leu Leu Ser Glu Ile Ala Asp Pro Thr Arg Phe  
1 5 10 15

Phe Thr Asp Asn Leu Leu Ser Pro Glu Asp Trp Gly Leu Gln Asn Ser  
20 25 30

Thr Leu Tyr Ser Gly Leu Asp Glu Val Ala Glu Glu Gln Thr Gln Leu  
35 40 45

Phe Arg Cys Pro Glu Gln Asp Val Pro Phe Asp Gly Ser Ser Leu Asp  
50 55 60

Val Gly Met Asp Val Ser Pro Ser Glu Pro Pro Trp Glu Leu Leu Pro  
65 70 75 80

Ile Phe Pro Asp Leu Gln Val Lys Ser Glu Pro Ser Ser Pro Cys Ser  
85 90 95

Ser Ser Ser Leu Ser Ser Glu Ser Ser Arg Leu Ser Thr Glu Pro Ser  
100 105 110

Ser Glu Ala Leu Gly Val Gly Glu Val Leu His Val Lys Thr Glu Ser  
115 120 125

Leu Ala Pro Pro Leu Cys Leu Leu Gly Asp Asp Pro Thr Ser Ser Phe  
130 135 140

Glu Thr Val Gln Ile Asn Val Ile Pro Thr Ser Asp Asp Ser Ser Asp  
145 150 155 160

Val Gln Thr Lys Ile Glu Pro Val Ser Pro Cys Ser Ser Val Asn Ser  
165 170 175

Glu Ala Ser Leu<sub>180</sub> Leu Ser Ala Asp Ser<sub>185</sub> Ser Ser Gln Ala Phe<sub>190</sub> Ile Gly  
 Glu Glu Val<sub>195</sub> Leu Glu Val Lys Thr<sub>200</sub> Glu Ser Leu Ser Pro<sub>205</sub> Ser Gly Cys  
 Leu Leu<sub>210</sub> Trp Asp Val Pro Ala<sub>215</sub> Pro Ser Leu Gly Ala<sub>220</sub> Val Gln Ile Ser  
 Met Gly Pro Ser Leu Asp<sub>230</sub> Gly Ser Ser Gly Lys<sub>235</sub> Ala Leu Pro Thr Arg<sub>240</sub>  
 Lys Pro Pro Leu Gln<sub>245</sub> Pro Lys Pro Val Val<sub>250</sub> Leu Thr Thr Val Pro<sub>255</sub> Met  
 Pro Ser Arg Ala<sub>260</sub> Val Pro Pro Ser Thr<sub>265</sub> Thr Val Leu Leu Gln<sub>270</sub> Ser Leu  
 Val Gln Pro<sub>275</sub> Pro Pro Val Ser Pro<sub>280</sub> Val Val Leu Ile Gln<sub>285</sub> Gly Ala Ile  
 Arg Val<sub>290</sub> Gln Pro Glu Gly Pro<sub>295</sub> Ala Pro Ser Leu Pro<sub>300</sub> Arg Pro Glu Arg  
 Lys Ser Ile Val Pro Ala<sub>310</sub> Pro Met Pro Gly Asn<sub>315</sub> Ser Cys Pro Pro Glu<sub>320</sub>  
 Val Asp Ala Lys Leu<sub>325</sub> Leu Lys Arg Gln Gln<sub>330</sub> Arg Met Ile Lys Asn<sub>335</sub> Arg  
 Glu Ser Ala Cys<sub>340</sub> Gln Ser Arg Arg Lys<sub>345</sub> Lys Lys Glu Tyr Leu<sub>350</sub> Gln Gly  
 Leu Glu Ala<sub>355</sub> Arg Leu Gln Ala Val<sub>360</sub> Leu Ala Asp Asn Gln<sub>365</sub> Gln Leu Arg  
 Arg Glu<sub>370</sub> Asn Ala Ala Leu Arg<sub>375</sub> Arg Arg Leu Glu Ala<sub>380</sub> Leu Leu Ala Glu  
 Asn Ser Glu Leu Lys Leu<sub>390</sub> Gly Ser Gly Asn Arg<sub>395</sub> Lys Val Val Cys Ile<sub>400</sub>  
 Met Val Phe Leu Leu<sub>405</sub> Phe Ile Ala Phe Asn<sub>410</sub> Phe Gly Pro Val Ser<sub>415</sub> Ile  
 Ser Glu Pro Pro<sub>420</sub> Ser Ala Pro Ile Ser<sub>425</sub> Pro Arg Met Asn Lys<sub>430</sub> Gly Glu  
 Pro Gln Pro<sub>435</sub> Arg Arg His Leu Leu<sub>440</sub> Gly Phe Ser Glu Gln<sub>445</sub> Glu Pro Val

Gln Gly Val Glu Pro Leu Gln Gly Ser Ser Gln Gly Pro Lys Glu Pro  
 450 455 460  
 Gln Pro Ser Pro Thr Asp Gln Pro Ser Phe Ser Asn Leu Thr Ala Phe  
 465 470 475 480  
 Pro Gly Gly Ala Lys Glu Leu Leu Leu Arg Asp Leu Asp Gln Leu Phe  
 485 490 495  
 Leu Ser Ser Asp Cys Arg His Phe Asn Arg Thr Glu Ser Leu Arg Leu  
 500 505 510  
 Ala Asp Glu Leu Ser Gly Trp Val Gln Arg His Gln Arg Gly Arg Arg  
 515 520 525  
 Lys Ile Pro Gln Arg Ala Gln Glu Arg Gln Lys Ser Gln Pro Arg Lys  
 530 535 540  
 Lys Ser Pro Pro Val Lys Ala Val Pro Ile Gln Pro Pro Gly Pro Pro  
 545 550 555 560  
 Glu Arg Asp Ser Val Gly Gln Leu Gln Leu Tyr Arg His Pro Asp Arg  
 565 570 575  
 Ser Gln Pro Ala Phe Leu Asp Ala Ile Asp Arg Arg Glu Asp Thr Phe  
 580 585 590  
 Tyr Val Val Ser Phe Arg Arg Asp His Leu Leu Leu Pro Ala Ile Ser  
 595 600 605  
 His Asn Lys Thr Ser Arg Pro Lys Met Ser Leu Val Met Pro Ala Met  
 610 615 620  
 Ala Pro Asn Glu Thr Leu Ser Gly Arg Gly Ala Pro Gly Asp Tyr Glu  
 625 630 635 640  
 Glu Met Met Gln Ile Glu Cys Glu Val Met Asp Thr Arg Val Ile His  
 645 650 655  
 Ile Lys Thr Ser Thr Val Pro Pro Ser Leu Arg Lys Gln Pro Ser Pro  
 660 665 670  
 Thr Pro Gly Asn Ala Thr Gly Gly Pro Leu Pro Val Ser Ala Ala Ser  
 675 680 685  
 Gln Ala His Gln Ala Ser His Gln Pro Leu Tyr Leu Asn His Pro  
 690 695 700

<210> 6  
 <211> 678  
 <212> PRT

&lt;213&gt; mouse

&lt;400&gt; 6

Leu Thr His Pro Ser Cys Glu Gly Glu Val Ser Val Ser Gly Lys Pro  
 1 5 10 15

Ala Cys Val Ala Gly Ala Met Glu Ser Pro Phe Ser Pro Val Leu Pro  
 20 25 30

His Gly Pro Asp Glu Asp Trp Glu Ser Thr Leu Phe Ala Glu Leu Gly  
 35 40 45

Tyr Phe Thr Asp Thr Asp Asp Val His Phe Asp Ala Ala His Glu Ala  
 50 55 60

Tyr Glu Asn Asn Phe Asp His Leu Asn Phe Asp Leu Asp Leu Met Pro  
 65 70 75 80

Trp Glu Ser Asp Leu Trp Ser Pro Gly Ser His Phe Cys Ser Asp Met  
 85 90 95

Lys Ala Glu Pro Gln Pro Leu Ser Pro Ala Ser Ser Ser Cys Ser Ile  
 100 105 110

Ser Ser Pro Arg Ser Thr Asp Ser Cys Ser Ser Thr Gln His Val Pro  
 115 120 125

Glu Glu Leu Asp Leu Leu Ser Ser Ser Gln Ser Pro Leu Ser Leu Tyr  
 130 135 140

Gly Asp Ser Cys Asn Ser Pro Ser Ser Val Glu Pro Leu Lys Glu Glu  
 145 150 155 160

Lys Pro Val Thr Gly Pro Gly Asn Lys Thr Glu His Gly Leu Thr Pro  
 165 170 175

Lys Lys Lys Ile Gln Met Ser Ser Lys Pro Ser Val Gln Pro Lys Pro  
 180 185 190

Leu Leu Leu Pro Ala Ala Pro Lys Thr Gln Thr Asn Ala Ser Val Pro  
 195 200 205

Ala Lys Ala Ile Ile Ile Gln Thr Leu Pro Ala Leu Met Pro Leu Ala  
 210 215 220

Lys Gln Gln Ser Ile Ile Ser Ile Gln Pro Ala Pro Thr Lys Gly Gln  
 225 230 235 240

Thr Val Leu Leu Ser Gln Pro Thr Val Val Gln Leu Gln Ser Pro Ala  
 245 250 255

Val Leu Ser Ser Ala Gln Pro Val Leu Ala Val Thr Gly Gly Ala Ala  
 260 265 270  
 Gln Leu Pro Asn His Val Val Asn Val Leu Pro Ala Pro Val Val Ser  
 275 280 285  
 Ser Pro Val Asn Gly Lys Leu Ser Val Thr Lys Pro Val Leu Gln Ser  
 290 300  
 Ala Thr Arg Ser Met Gly Ser Asp Ile Ala Val Leu Arg Arg Gln Gln  
 305 310 315 320  
 Arg Met Ile Lys Asn Arg Glu Ser Ala Cys Gln Ser Arg Lys Lys Lys  
 325 330 335  
 Lys Glu Tyr Met Leu Gly Leu Glu Ala Arg Leu Lys Ala Ala Leu Ser  
 340 345 350  
 Glu Asn Glu Gln Leu Lys Lys Glu Asn Gly Ser Leu Lys Arg Gln Leu  
 355 360 365  
 Asp Glu Val Val Ser Glu Asn Gln Arg Leu Lys Val Pro Ser Pro Lys  
 370 375 380  
 Arg Arg Ala Val Cys Val Met Ile Val Leu Ala Phe Ile Met Leu Asn  
 385 390 395 400  
 Tyr Gly Pro Met Ser Met Leu Glu Gln Glu Ser Arg Arg Val Lys Pro  
 405 410 415  
 Ser Val Ser Pro Ala Asn Gln Arg Arg His Leu Leu Glu Phe Ser Ala  
 420 425 430  
 Lys Glu Val Lys Asp Thr Ser Asp Gly Asp Asn Gln Lys Asp Ser Tyr  
 435 440 445  
 Ser Tyr Asp His Ser Val Ser Asn Asp Lys Ala Leu Met Val Pro Ser  
 450 455 460  
 Glu Glu Pro Leu Leu Tyr Met Pro Pro Pro Pro Cys Gln Pro Leu Ile  
 465 470 475 480  
 Asn Thr Thr Glu Ser Leu Arg Leu Asn His Glu Leu Arg Gly Trp Val  
 485 490 495  
 His Arg His Glu Val Glu Arg Thr Lys Ser Arg Arg Met Thr Asn Ser  
 500 505 510  
 Gln Gln Lys Ala Arg Ile Leu Gln Gly Ala Leu Glu Gln Gly Ser Asn  
 515 520 525

Ser Gln Leu Met Ala Val Gln Tyr Thr Glu Thr Thr Ser Ile Ser Arg  
530 535 540

Asn Ser Gly Ser Glu Leu Gln Val Tyr Tyr Ala Ser Pro Gly Ser Tyr  
545 550 555 560

Gln Gly Phe Phe Asp Ala Ile Arg Arg Arg Gly Asp Thr Phe Tyr Val  
565 570 575

Val Ser Phe Arg Arg Asp His Leu Leu Leu Pro Ala Thr Thr His Asn  
580 585 590

Lys Thr Thr Arg Pro Lys Met Ser Ile Val Leu Pro Ala Ile Asn Ile  
595 600 605

Asn Asp Asn Val Ile Asn Gly Gln Asp Tyr Glu Val Met Met Gln Ile  
610 615 620

Asp Cys Gln Val Met Asp Thr Arg Ile Leu His Ile Lys Ser Ser Ser  
625 630 635 640

Val Pro Pro Tyr Leu Arg Asp His Gln Arg Asn Gln Thr Ser Thr Phe  
645 650 655

Phe Gly Ser Pro Pro Thr Thr Thr Glu Thr Thr His Val Val Ser Thr  
660 665 670

Ile Pro Glu Ser Leu Gln  
675

<210> 7  
<211> 699  
<212> PRT  
<213> murine

<400> 7

Met Ala Glu Leu Met Leu Leu Ser Glu Ile Ala Asp Pro Thr Arg Phe  
1 5 10 15

Phe Thr Asp Asn Leu Leu Ser Pro Glu Asp Trp Asp Ser Thr Leu Tyr  
20 25 30

Ser Gly Leu Asp Glu Val Ala Glu Glu Gln Ala Gln Leu Phe Arg Cys  
35 40 45

Val Glu Gln Asp Val Pro Phe Asp Ser Ser Ser Leu Asp Val Gly Met  
50 55 60

Asp Val Ser Pro Pro Glu Pro Pro Trp Asp Pro Leu Pro Ile Phe Pro  
65 70 75 80

Asp Leu Gln Val Lys Ser Glu Pro Ser Ser Pro Cys Ser Ser Ser Ser  
Page 9

85 90 95  
 Leu Ser Ser Glu Ser Ser His Leu Ser Thr Glu Pro Pro Ser Gln Val  
 100 105 110  
 Pro Gly Val Gly Glu Val Leu His Val Lys Met Glu Ser Leu Ala Pro  
 115 120 125  
 Pro Leu Cys Leu Leu Gly Asp Asp Pro Ala Ser Pro Phe Glu Thr Val  
 130 135 140  
 Gln Ile Thr Val Gly Ser Ala Ser Asp Asp Leu Ser Asp Ile Gln Thr  
 145 150 155 160  
 Lys Leu Glu Pro Ala Ser Pro Ser Ser Ser Val His Ser Glu Ala Ser  
 165 170 175  
 Leu Leu Ser Ala Asp Ser Pro Ser Gln Pro Phe Ile Gly Glu Glu Val  
 180 185 190  
 Leu Glu Val Lys Thr Glu Ser Pro Ser Pro Pro Gly Cys Leu Leu Trp  
 195 200 205  
 Asp Val Pro Ala Ser Ser Leu Gly Ala Val Gln Ile Ser Met Gly Pro  
 210 215 220  
 Ser Pro Asp Ser Ser Ser Gly Lys Ala Pro Ala Thr Arg Lys Pro Pro  
 225 230 235 240  
 Leu Gln Pro Lys Pro Val Val Leu Thr Thr Val Pro Val Pro Pro Arg  
 245 250 255  
 Ala Gly Pro Thr Ser Ala Ala Val Leu Leu Gln Pro Leu Val Gln Gln  
 260 265 270  
 Pro Ala Val Ser Pro Val Val Leu Ile Gln Gly Ala Ile Arg Val Gln  
 275 280 285  
 Pro Glu Gly Pro Ala Pro Ala Ala Pro Arg Pro Glu Arg Lys Ser Ile  
 290 295 300  
 Val Pro Ala Pro Met Pro Gly Asn Ser Cys Pro Pro Glu Val Asp Ala  
 305 310 315 320  
 Lys Leu Leu Lys Arg Gln Gln Arg Met Ile Lys Asn Arg Glu Ser Ala  
 325 330 335  
 Cys Gln Ser Arg Arg Lys Lys Lys Glu Tyr Leu Gln Gly Leu Glu Ala  
 340 345 350  
 Arg Leu Gln Ala Val Leu Ala Asp Asn Gln Gln Leu Arg Arg Glu Asn

| 355 |     |     |     |     | 360 |     |     |     |     | 365 |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Ala | Leu | Arg | Arg | Arg | Leu | Glu | Ala | Leu | Leu | Ala | Glu | Asn | Ser | Gly |
|     | 370 |     |     |     |     | 375 |     |     |     |     | 380 |     |     |     |     |
| Leu | Lys | Leu | Gly | Ser | Gly | Asn | Arg | Lys | Val | Val | Cys | Ile | Met | Val | Phe |
| 385 |     |     |     |     | 390 |     |     |     |     | 395 |     |     |     |     | 400 |
| Leu | Leu | Phe | Ile | Ala | Phe | Asn | Phe | Gly | Pro | Val | Ser | Ile | Ser | Glu | Pro |
|     |     |     |     | 405 |     |     |     |     | 410 |     |     |     |     | 415 |     |
| Pro | Pro | Ala | Pro | Met | Ser | Pro | Arg | Met | Ser | Arg | Glu | Glu | Pro | Arg | Pro |
|     |     |     | 420 |     |     |     |     | 425 |     |     |     |     | 430 |     |     |
| Gln | Arg | His | Leu | Leu | Gly | Phe | Ser | Glu | Pro | Gly | Pro | Ala | His | Gly | Met |
|     |     | 435 |     |     |     |     | 440 |     |     |     |     | 445 |     |     |     |
| Glu | Pro | Leu | Arg | Glu | Ala | Ala | Gln | Ser | Pro | Gly | Glu | Gln | Gln | Pro | Ser |
|     | 450 |     |     |     |     | 455 |     |     |     |     | 460 |     |     |     |     |
| Ser | Ala | Gly | Arg | Pro | Ser | Phe | Arg | Asn | Leu | Thr | Ala | Phe | Pro | Gly | Gly |
| 465 |     |     |     |     | 470 |     |     |     |     | 475 |     |     |     |     | 480 |
| Ala | Lys | Glu | Leu | Leu | Leu | Arg | Asp | Leu | Asp | Gln | Leu | Phe | Leu | Ser | Ser |
|     |     |     |     | 485 |     |     |     |     | 490 |     |     |     |     | 495 |     |
| Asp | Cys | Arg | His | Phe | Asn | Arg | Thr | Glu | Ser | Leu | Arg | Leu | Ala | Asp | Glu |
|     |     |     | 500 |     |     |     |     | 505 |     |     |     |     | 510 |     |     |
| Leu | Ser | Gly | Trp | Val | Gln | Arg | His | Gln | Arg | Gly | Arg | Arg | Lys | Ile | Pro |
|     |     | 515 |     |     |     |     | 520 |     |     |     |     | 525 |     |     |     |
| His | Arg | Ala | Gln | Glu | Arg | Gln | Lys | Ser | Gln | Leu | Arg | Lys | Lys | Ser | Pro |
|     | 530 |     |     |     |     | 535 |     |     |     |     | 540 |     |     |     |     |
| Pro | Val | Lys | Pro | Val | Pro | Thr | Gln | Pro | Pro | Gly | Pro | Pro | Glu | Arg | Asp |
| 545 |     |     |     |     | 550 |     |     |     |     | 555 |     |     |     |     | 560 |
| Pro | Val | Gly | Gln | Leu | Gln | Leu | Tyr | Arg | His | Pro | Gly | Arg | Ser | Gln | Pro |
|     |     |     |     | 565 |     |     |     |     | 570 |     |     |     |     | 575 |     |
| Glu | Phe | Leu | Asp | Ala | Ile | Asp | Arg | Arg | Glu | Asp | Thr | Phe | Tyr | Val | Val |
|     |     |     | 580 |     |     |     |     | 585 |     |     |     |     | 590 |     |     |
| Ser | Phe | Arg | Arg | Asp | His | Leu | Leu | Leu | Pro | Ala | Ile | Ser | His | Asn | Lys |
|     |     | 595 |     |     |     |     | 600 |     |     |     |     | 605 |     |     |     |
| Thr | Ser | Arg | Pro | Lys | Met | Ser | Leu | Val | Met | Pro | Ala | Met | Ala | Pro | Asn |
|     | 610 |     |     |     |     | 615 |     |     |     |     | 620 |     |     |     |     |
| Glu | Thr | Val | Ser | Gly | Arg | Gly | Pro | Pro | Gly | Asp | Tyr | Glu | Glu | Met | Met |

625                      630                      635                      640  
 Gln Ile Glu Cys Glu Val Met Asp Thr Arg Val Ile His Ile Lys Thr  
                                  645                                   650                                   655  
 Ser Thr Val Pro Pro Ser Leu Arg Lys Gln Pro Ser Pro Ser Pro Gly  
                                  660                                   665                                   670  
 Asn Thr Thr Gly Gly Pro Leu Pro Gly Ser Ala Ala Ser Pro Ala His  
                                  675                                   680                                   685  
 Gln Ala Ser Gln Pro Leu Tyr Leu Asn His Pro  
                                  690                                   695

<210> 8  
 <211> 2474  
 <212> DNA  
 <213> human

<400> 8  
 aagatattaa tcacggagtt ccagggaaaa ggaacttggt aaatggggga gccggctggg 60  
 gttgccggca ccatggagtc accttttagc ccgggactct ttcacaggct ggatgaagat 120  
 tgggattctg ctctctttgc tgaacttggt tatttcacag aactgatga gctgcaattg 180  
 gaagcagcaa atgagacgta tgaaaacaat ttgataatc ttgattttga tttggatttg 240  
 ttaccttggg agtcagacat ttgggacatc aacaaccaa tctgtacagt taaagatatt 300  
 aaggcagaac ccagccact ttctccagcc tcctcaagtt attcagtctc atctcctcgg 360  
 tcagtggact cttattcttc aactcagcat gttcctgagg agttggattt gtcttctagt 420  
 tctcagatgt ctcccccttc cttatatggt gaaaactcta atagtctctc ttcaccggag 480  
 ccactgaagg aagataagcc tgtcactggt tctaggaaca agactgaaaa tggactgact 540  
 ccaaagaaaa aaattcaggt gaattcaaaa cttcaattc agcccaagcc tttattgctt 600  
 ccagcagcac ccaagactca acaaaactcc agtggtccag caaaaaccat cattattcag 660  
 acagtaccaa cgcttatgcc attggcaaag cagcaaccaa ttatcagttt acaacctgca 720  
 cccactaaag gccagacggt tttgctgtct cagcctactg tggtaact tcaagcacct 780  
 ggagttctgc cctctgctca gccagtcctt gctgttgctg ggggagtcac acagctccct 840  
 aatcacgtgg tgaatgtggt accagcccct tcagcgaata gccagtgaa tggaaaactt 900  
 tccgtgacta aacctgtcct acaaagtacc atgagaaatg tcggttcaga tattgctgtg 960  
 ctaaggagac agcaacgtat gataaaaaat cgagaatccg cttgtcagtc tcgcaagaag 1020  
 aagaaagaat atatgctagg gttagaggcg agattaaagg ctgccctctc agaaaacgag 1080  
 caactgaaga aagaaaatgg aactactgaag cggcagctgg atgaagttgt gtcagagaac 1140  
 cagaggctta aagtccttag tcaaagcga agagttgtct gtgtgatgat agtattggca 1200  
 ttataatac tgaactatgg acctatgagc atgttggaac aggattccag gagaatgaac 1260  
 cctagtgtgg gacctgcaaa tcaaaggagg caccttctag gattttctgc taaagaggca 1320

caggacacat cagatggtat tatccagaaa aacagctaca gatatgatca ttctgtttca 1380  
 aatgacaaag ccctgatggt gctaactgaa gaaccattgc ttacattcc cccacctcct 1440  
 tgtcagcccc taattaatac aacagagtct ctcaggttaa atcatgaact tcgaggatgg 1500  
 gttcatagac atgaagtaga aaggaccaag tctagaagaa tgacaaataa tcaacagaaa 1560  
 acccggtattc ttcaggggtgt tgtggaacag ggctcaaatt ctcagctgat ggctgttcaa 1620  
 tacacagaaa ccactagtag tatcagcagg aactcagga gtgagctaca agtgtattat 1680  
 gcttcacca gaagttatca agactttttt gaagccatcc gcagaagggg agacacattt 1740  
 tatgttgtgt catttcgaag ggatcacctg ctgttaccag ctaccacca taacaagacc 1800  
 acaagacca aaatgtcaat tgtgttacca gcaataaaca taaatgagaa tgtgatcaat 1860  
 gggcaggact acgaagtgat gatgcagatt gactgtcagg tgatggacac caggatcctc 1920  
 catatcaaaa gttcgtcggg tcctccttac ctccgagatc agcagaggaa tcaaaccaac 1980  
 accttctttg gctccccctc cgcagccaca gaggcaacct acgttgtcag caccatccct 2040  
 gagtcattac aatagcacc gcagctatgt ggaaaactga gcgtgggacc cccagactga 2100  
 agagcagggt agcaaaatgc tgcttttcct tgggtggcagg cagagaactg ttcgtactag 2160  
 aattcaagga gaaaagaaga agaaataaaa gaagctgctc cttttttcat catctacca 2220  
 tctatttggg aagcactgga attcagatgc aagagaacaa tgtttcttca gtggcaaatg 2280  
 tagccctgca tcctccagtg ttacctggtg tagatttttt tttctgtacc tttctaaacc 2340  
 tctcttcct ctgtgatggt tttgtgttta aacagtcatc ttcttttaaa taatatccac 2400  
 ctctcctttt tgccatttca cttattgatt cataaagtga attttattta aagctaaaaa 2460  
 aaaaaaaaaa aaaa 2474

<210> 9  
 <211> 2622  
 <212> DNA  
 <213> human

<400> 9  
 aaccgtctcc tgggtggggg gtggggggga aagatggcgg agctgatgct gctcagcgag 60  
 attgctgacc cgacgcgttt cttcaccgac aacctgctta gcccgaggga ctgggggtctg 120  
 cagaacagca ccttgatttc tggcctagat gaagtggccg aggagcagac gcagctcttc 180  
 cgttgcccgg agcaggatgt cccgtttgac ggcagctccc tggacgtggg gatggatgtc 240  
 agcccctctg agcccccatt ggaactcctg ccgatcttcc cagatcttca ggtgaagtct 300  
 gagccatctt cccctgctc ttctcctcc ctcagctccg agtcatcgcg tctctccaca 360  
 gagccatcca gcgaggctct tggggtaggg gaggtgctcc atgtgaagac agagtccttg 420  
 gcacccccac tgtgtctcct gggagatgac ccaacatcct catttgaaac cgtccagatc 480  
 aatgttatcc ccacctctga tgattcctca gatgtccaga ccaagataga acctgtctct 540  
 ccatgttctt ccgtcaactc tgaggcctcc ctgctctcag ccgactcctc cagccaggct 600

|            |            |            |            |            |             |      |
|------------|------------|------------|------------|------------|-------------|------|
| tttataggag | aggaggtcct | ggaagtgaag | acagagtccc | tgtccccttc | aggatgcctc  | 660  |
| ctgtgggatg | tcccagcccc | ctcacttgga | gctgtccaga | tcagcatggg | cccatccctt  | 720  |
| gatggctcct | caggcaaagc | cctgcccacc | cggaagccgc | cactgcagcc | caaacctgta  | 780  |
| gtgctaacca | ctgtcccaat | gccatccaga | gctgtgcctc | ccagcaccac | agtccttctg  | 840  |
| cagtccctcg | tccagccacc | cccagtgtcc | ccagttgtcc | tcatccaggg | tgctattcga  | 900  |
| gtccagcctg | aagggccggc | tccctctcta | ccacggcctg | agaggaagag | catcgttccc  | 960  |
| gctcctatgc | ctggaaactc | ctgcccgcct | gaagtggatg | caaagctgct | gaagcggcag  | 1020 |
| cagcgaatga | tcaagaaccg | ggagtcagcc | tgccagtccc | ggagaaagaa | gaaagagtat  | 1080 |
| ctgcagggac | tggaggctcg | gctgcaagca | gtactggctg | acaaccagca | gctccgccga  | 1140 |
| gagaatgctg | ccctccggcg | gcggctggag | gccctgctgg | ctgaaaacag | cgagctcaag  | 1200 |
| ttagggctcg | gaaacaggaa | ggtggtctgc | atcatggctt | tccttctctt | cattgccttc  | 1260 |
| aactttggac | ctgtcagcat | cagtgagcct | ccttcagctc | ccatctctcc | tcggatgaac  | 1320 |
| aagggggagc | ctcaaccccc | gagacacttg | ctggggttct | cagagcaaga | gccagttcag  | 1380 |
| ggagttgaac | ctctccaggg | gtcctcccag | ggccctaagg | agccccagcc | cagccccaca  | 1440 |
| gaccagccca | gtttcagcaa | cctgacagcc | ttccctgggg | gcgccaagga | gctactacta  | 1500 |
| agagacctag | accagctctt | cctctctctt | gattgccggc | acttcaaccg | cactgagtcc  | 1560 |
| ctgaggcttg | ctgacgagtt | gagtggctgg | gtccagcgcc | accagagagg | ccggagggaag | 1620 |
| atccctcaga | gggccagga  | gagacagaag | tctcagccac | ggaagaagtc | acctccagtt  | 1680 |
| aaggcagtcc | ccatccaacc | ccctggaccc | ccagaaaggg | attctgtggg | ccagctgcaa  | 1740 |
| ctatatcgcc | accagaccg  | ttcgagcca  | gcattcttgg | atgcaattga | ccgacgggaa  | 1800 |
| gacacatttt | atgttgcttc | tttccgaagg | gaccacctgc | tgctcccagc | catcagccac  | 1860 |
| aacaagacct | ccgggcccaa | gatgtccctg | gtgatgcctg | ccatggcccc | caatgagacc  | 1920 |
| ctgtcaggcc | gtggggcccc | gggggactat | gaggagatga | tgagatcga  | gtgtgaggtc  | 1980 |
| atggacacca | gggtgattca | catcaagacc | tccacagtgc | ccccctcgct | ccgaaaacag  | 2040 |
| ccatcccca  | ccccaggcaa | tgccacaggt | ggccccttgc | cagtctctgc | agccagccag  | 2100 |
| gcccaccagg | cctcccacca | gcccctctac | ctcaatcatc | cctgacctct | gccattcaca  | 2160 |
| ctgacttaga | acggggggag | ggggtaccag | gtggccaggt | gggactgttt | caaatttccc  | 2220 |
| tgatccccag | gcttggggca | attggtaaag | gaaagagcag | gtgtgggggt | taagcactta  | 2280 |
| tttgaggtgg | gggtgttcac | ctctcttctc | atcccttttc | agaatatagg | gctcctctca  | 2340 |
| ttcctgtgaa | ccccagctcc | tggcttcttt | gtttgagggg | attgtgtgag | gttcagttgt  | 2400 |
| ggggtgggtg | gtgagctgct | gcataatttt | tattttgttt | ctctagtgtt | atggcagtg   | 2460 |
| aggtgggaat | ttagtcccca | ggtgggacaa | gggaagtttt | ttcattttgg | agctagttac  | 2520 |
| tgggagtaag | ggaggggtgg | gtggggggga | gttcagggtt | atgtgtgtgc | atttcttttt  | 2580 |
| tattattatt | aaataaaca  | cttgaggga  | gttgaaaaaa | aa         |             | 2622 |

<210> 10  
 <211> 4447  
 <212> DNA  
 <213> murine

<400> 10  
 ccggagggag aggtgtctgt ttcggggaag ccggcttggt ttgccggcgc catggagtcg 60  
 ccttttagtc cggttcttcc tcatggacca gatgaagact gggagtcgac gttgtttgct 120  
 gaacttggct atttcacaga cactgatgat gtgcactttg atgcagcaca tgaggcttat 180  
 gaaaataatt ttgatcatct taattttgat ttggatttga tgccttgga gtcagacctt 240  
 tggagccccg gcagccactt ctgctcagac atgaaggcag agccccagcc tctttctccg 300  
 gcttctcca gttgtccat ctctctcct cgggccacag actcgtgttc ttcaactcag 360  
 cacgttctg aggagttgga tttgttgtct agttctcagt ccccccttc cttatatggc 420  
 gacagctgta atagcccctc ctctgtagag cactgaagg aagagaagcc tgtcactggt 480  
 cctggaaca aaacagaaca tggactgact ccaaagaaaa aaattcagat gagtttaaaa 540  
 ccttcagttc agcccaagcc ttattactt ccagcagcgc ccaagactca aaccaatgcc 600  
 ggtgtcccag caaaagccat catcattcag aactaccag cccttatgcc actggcaaag 660  
 cagcagtcga ttatcagcat acagcctgcg ccaccaaag gccagactgt tttgctctct 720  
 cagccgactg tggttcaact tcagagccct gcggttctgt cgtctgctca gccggttctt 780  
 gcagtcactg ggggagccgc acagctacct aaccatgtgg tgaattgttg ctggccagcc 840  
 ccctgtggtg agcagcccgg tgaatggaaa actttccgtg actaaacctg ttctacaaag 900  
 tgccaccaga agtatgggtt cggatatcgc tgtgctgagg agacagcagc ggatgataaa 960  
 gaaccgagag tctgcttgct agtcgcgcaa gaagaagaaa gagtatatgc taggactgga 1020  
 ggccaggcct caaggctgcc ctctcataga atgagcagct gtagaaggag aatggctccc 1080  
 tgaagcgaca gctggacgag gtggtgtcag agaaccagag gctcaaagtc ccaagtccaa 1140  
 agcgaagagc tgtctgtgtg atgatagtat tagcatttat aatgctgaac tatgggcccc 1200  
 tgagcatgct ggagcaagaa tcccgaagag tgaaacctag tgtgagccct gccaatcaga 1260  
 ggaggcatct cttggaattt tcagcaaaag aagttaaaga cacatcagat ggtgacaacc 1320  
 agaaagacag ttacagctat gatcactctg tgtccaatga caaagcttta atggtgctaa 1380  
 gtgaagagcc attgctttat atgcctccac ctccatgtca acccctgatt aacacaacag 1440  
 agtctctcag gttgaaccat gaacttcgag gctgggttca tagacatgaa gtggaaagga 1500  
 ccaaacttag aagaatgaca aatagccaac agaaagcccc cattctccag ggtgctctgg 1560  
 aacagggctc taattctcag ctgatggctg tccagtacac agaaaccact agcatcagta 1620  
 ggaattctgg gagtgagctg caagtgtatt acgcctcccc tggaagttac caaggcttct 1680  
 ttgacgccat ccgcaggagg ggagatacgt ttacgttgt ctcatctcga agggatcatc 1740  
 tgctattacc agctaccacc cacaacaaga ccacaagacc aaaaatgtca attgtattac 1800  
 cagcaataaa cataaatgat aatgtgatca atgggcagga ctatgaagta atgatgcaga 1860

|                                                                   |      |
|-------------------------------------------------------------------|------|
| ttgactgtca ggtgatggac accaggatcc tccacatcaa aagctcctcg gttccccctt | 1920 |
| atctccggga tcatcagcgg aaccaaacca gcaccttctt tggttcccct ccaacaacca | 1980 |
| cagagacgac ccatgtggtc agcaccatcc ctgagtcgtt gcagtagtgc ccgagctgcg | 2040 |
| ctggacagca gagactgaag agctggtgaa gatgctgctc tctgcctctt cggcaagcag | 2100 |
| agacttgctt tgtacgcaac tccaggggaa gaggaagaga gaacaggaag tgcgctgctt | 2160 |
| gtcaccgtcc acccagtggg gtggaacatg ctagcgagca attctctggt ggcagtgcag | 2220 |
| ccctgtgggc agtgtcgcct ggtgttggtt ctgctgtgtc atctttagtg cttttctcaa | 2280 |
| tgtgtgtttg gttctcagtt atcttccttc aggtcagacc cacttcctct tctgtccact | 2340 |
| gcacttcctg gtgcagtaaa gagatttgta tttaaagctt tagaacacat gtcatgtgg  | 2400 |
| tttccaccaa ttggctttct ctctcctttg gttcaaattc attctgaatg ttatacttga | 2460 |
| gaaaacacat ttcaaaaaac cgagcagcca aaaacatccc acaaagagtc aaaacagttt | 2520 |
| agagtttggg taaagggatt atctccagtt ggtaagagtt tatttttact tgtgatttgt | 2580 |
| ggttcagccc tggacaaata actgttggtg gggtcacaga gtgagccaca cactggagac | 2640 |
| aaggggaagg aaggccagtg gtggaatgta aggggaagtg actccatttt catatgtatt | 2700 |
| taaacacaga gttcctgtgg cctcggtgag ctgagagcta tagccaccct cagtgttgga | 2760 |
| actcggctaa tcagcagaga tcttcaaaga tctcagggca catgcttgcc tctcattgtg | 2820 |
| gaccctcagc ccagagcata ctctgtgaa accagactca gcaaagggac ttggagggtca | 2880 |
| ctaggcttaa gcaagactag agagtttccc ttaaggacca acagtgcaca gagcaagcat | 2940 |
| ggcttcccag agaagctgca gcacagtatg gtgaagtctt cagtttttcc agtggaagaa | 3000 |
| tgataaagga attaagctct ctttggtgtt gctatggctg tgaacatggc tttaatccta | 3060 |
| gcaccatttg gaaggaaagg caggctttgt ttgatatcag cctggcctac atttcaaatt | 3120 |
| ccaggacagg acagctaaag ctatataaag aaccacctc aaaaaataga tgaatgaata  | 3180 |
| aatgagtaaa taaacaaata caaacaataa gcaaagttat gttcacatat attttattgt | 3240 |
| attttgctg cttccttcac catagcaagc agccacattt ctattgcact gtacattgta  | 3300 |
| cgttacaagt tcacagaaat ggatgccagg actcatgtca gtcatgtgct gcctcccttc | 3360 |
| ccaggatttc agcaggttct catagactct tcccagcctg gcttgcccat tgtcagggtg | 3420 |
| tcccattcca gtaagcacia tggcggctaa gtcctcttct ctctacaagg agtgacacac | 3480 |
| agtcagggtca tcttttgctt gtggcccat tatgcctggc actgttcacc aacaactgtt | 3540 |
| ccctggacag cactgctgcc atctaagcta aggtgagatg ttttcggggc agggccattc | 3600 |
| ttgctgaatt cagtgccgca gtccatcctg attggctctc gggtgatttt cagacaagac | 3660 |
| ctgtttgtcc cgggggctgg tcctctaatt ggtgccaagg agaagatacc aaatacatgg | 3720 |
| agtaccttta ggagtagcca tttgtggggg aggttgggct accctgtggc catgttcttc | 3780 |
| ctgcctgtga agcagctcaa aacgaggatg tgactgtggg ctgtggacag aggcagcaca | 3840 |
| cgcattcctg atgctgatct gctgagacac gaatagaatc tgcagtgact ccagtgtacc | 3900 |

```

agtgcctcag atcaaagacc tcaatagtgt cacgtttgct aaggctgatg cctctcctac 3960
aggtaacagt ggggatgacc gttggaaggc acagccaaag agcagacaga agttaagggtg 4020
gccacagcac aggtcagggg tccaaggagc tggggaggac tgctcaaaac tagtctggaa 4080
gcttgccctt tctgctcctg ctgaccatca ggtcctgtca ttaccactct cagggtccgtc 4140
ttatgagatg aggaatgggg ccctcctcag gggagagttt cagaaatgag ggaaaggcaa 4200
ttatagatag aaagaagtat cctgccatth aaattgctga aagagctaga atccctgggc 4260
tcggtagttt gtatcttaat gtttgtgctg tagcacaggc ccattggaga ggaaaagctg 4320
ttgtcctggg agcaaagtaa gcagccattc aggtctcatt ttttattttg gtatgcttgc 4380
ccttgggtgt ttatagcccc gaactgtagg agctatgtat gtacataata tatatatattt 4440
ttaattt 4447

```

```

<210> 11
<211> 2514
<212> DNA
<213> murine

```

```

<400> 11
gcggggagcc ggctcatggt ggggggtggg gggaagatgg cggagctgat gctcctcact 60
gagatcgccg acccgacgcg cttcttcacc gacaacctgc tgagtccgga ggactgggac 120
agcaccttgt acagtggcct ggatgaagtg gccgaggagc aggcacagtt gttccgttgc 180
gtggagcagg atgtcccgtt tgacagcagc tctctggatg tggggatgga tgtcagcccc 240
cctgagcccc cttgggaccc tctaccatc tcccagatc ttcagggtgaa gtccgagcca 300
tcctctccct gctcgtcctc ctccctcagc tcagagtcct cacatctttc cacagagccc 360
cccagccagg tccctggtgt aggcgaggtg ctgcatgtga agatggagtc cctggcaccc 420
ccactctgcc tgctggggga tgatccagca tcccccttg aaacgggtcca gatcactgtg 480
ggctctgcct ctgatgatct ttcagatata cagaccaagc tggaacctgc ctctccgtct 540
tcttctgtcc actctgaggc ctcttctgtg tcagcagact ctcccagtca gccttttata 600
ggagaggagg ttctggaagt gaagacagag tctccgtccc ctccagggtg cctcctgtgg 660
gatgtcccag cctcttcgct cggagctgtc cagatcagca tgggtccatc ccctgatagt 720
tcctcagggg aagctccggc cactcggaag cctccactgc agcccaagcc tgtggtacta 780
accacagttc cggtgccacc tagagctggg cctaccagcg ctgccgtcct cctgcaaccc 840
ctggtccagc agcctgcggt gtccccagtg gtcctcatcc aagggtgtat ccgagtccag 900
cctgaagggc cagctccccg agctccccgg cctgagagga agagcattgt tccagcccct 960
atgccgggga actcctgccc gcctgaagtg gatgcaaagc tggtgaagcg gcagcagcgg 1020
atgatcaaga atcgagagtc ggcctgccag tcccgccgca agaagaaaga gtacctgcca 1080
aggcctggag gccccggctg caggctgtgc tggccgacaa ccagcagctg cgaggggaga 1140
acgctgccct ccggcggcgg ctggaggccc tgctggcaga gaacagcggg ctcaagctgg 1200

```

```

ggctctgggaa caggaagggtt gtctgcatca tggctcttct tctcttcatt gccttcaact 1260
tttggcctgt gagcatcagc gagccgcctc cagctcccat gtctcctcgg atgagcaggg 1320
aggaacctcg accccagagg cacctgctgg gcttctcaga accagggcca gctcatggca 1380
tggaaccctt tcgggaagcc gccagagacc ccggggagca gcagcccagc tctgcaggca 1440
ggcccagctt cagaaacctg acggccttcc ccgggggagc caaggaggct gctgctgaga 1500
gacctggacc agctcttctt ctctcagac tgtcgccatt tcaaccgaac tgagtctctg 1560
aggcttgctg atgagctgag tggctgggtc caacgtcacc agagaggctg acggaagata 1620
cctcacaggg cccaggagag acagaagtct cagctacgga agaagtctcc tccagtgaaa 1680
cctgtcccca cccaacctcc aggaccccct gaaagggacc ccgtgggcca gctgcagctc 1740
taccgccacc ccggccgctc gcagccggag tttctagacg caattgaccg gaggaggat 1800
accttctatg ttgtctcctt ccgaagggac cacctgctgc tcccagccat cagccaccac 1860
aagacatcca ggcccaagat gtcgctggtg atgccagcca tggcccccaa tgagaccgtg 1920
tcaggccggg gccccccagg ggactatgag gagatgatgc agatcgagtg tgaggtcatg 1980
gacaccaggg tgattcacat caagacctct acggtgcccc cctcgctccg gaagcagccg 2040
tccccatccc cgggcaatac cacaggtggc cccttgccag gctccgcagc tagtcctgcc 2100
catcaggcct cccagcccct ttacctcaat caccctgac atcctcacct cacagtgact 2160
tagaaccggg ttaggggaacc tgatcctggg gtcgggggc aattgtaaag gaagacgggg 2220
tgtgggggtt aagcacttag tgggactagg gtgggtggtt cacctctctt ctactcttt 2280
ccagaaatat agggctcctc tcattcctgc actcccagtc ctctttcccc gagggtagct 2340
cgtgagggtt tccccatat cctcttcatt ctctccttta tctgtttggg agtcaagggtg 2400
ggactaggtc gccagggtggg acaagggatg gttgtgggtg gcagaagtca gtttatgtgt 2460
gtgcgtatct tttttttatt attattaaat aaacaacgtg gaggggtgta aagg 2514

```